References

Ref. 1. Burchenal JH, et al. (1948) Cancer, 1: 399. Available from: https://doi.org/10.1002/1097-0142(194809)1:3<399::aid-cncr2820010305>3.0.co;2-f

Ref. 2. Farber S, et al. (1948) N Engl J Med, 238: 787. Available from: https://doi.org/10.1056/NEJM194806032382301

Ref. 3. Pearson OH, et al. (1950) J Am Med Assoc, 144: 1349. Available from: https://doi.org/10.1001/jama.1950.02920160023005

Ref. 4. Burchenal JH, et al. (1953) Blood, 8: 965. Available from: https://doi.org/10.1182/blood.V8.11.965.965

Ref. 5. NCI Childhood Cancer Data Initiative. NCI NCCR*Explorer. Accessed: June 15, 2025. Available from: https://nccrexplorer.ccdi.cancer.gov/application.html

Ref. 6. O’Leary M, et al. (2008) Semin Oncol, 35: 484. Available from: https://doi.org/10.1053/j.seminoncol.2008.07.008

Ref. 7. Erdmann F, et al. (2021) Cancer Epidemiol, 71: 101733. Available from: https://doi.org/10.1016/j.canep.2020.101733

Ref. 8. Withycombe JS, et al. (2019) J Pediatr Oncol Nurs, 36: 24. Available from: https://doi.org/10.1177/1043454218810141

Ref. 9. Lupo PJ, et al. (2025) J Natl Cancer Inst. Available from: https://doi.org/10.1093/jnci/djaf134

Ref. 10. Linabery AM, et al. (2008) Cancer, 113: 2575. Available from: https://doi.org/10.1002/cncr.23866

Ref. 11. NCI Surveillance, Epidemiology, and End Results Program. NCI SEER*Explorer. Accessed: June 31, 2025. Available from: https://seer.cancer.gov/statistics-network/explorer/application.html

Ref. 12. Kruse A, et al. (2020) Int J Mol Sci, 21. Available from: https://doi.org/10.3390/ijms21031054

Ref. 13. Hunger SP, et al. (2015) N Engl J Med, 373: 1541. Available from: https://doi.org/10.1056/NEJMra1400972

Ref. 14. DuBois SG, et al. (2025) Pediatr Blood Cancer, 72: e31831. Available from: https://doi.org/10.1002/pbc.31831

Ref. 15. Armstrong GT, et al. (2016) N Engl J Med, 374: 833. Available from: https://doi.org/10.1056/NEJMoa1510795

Ref. 16. Siegel RL, et al. (2025) CA Cancer J Clin, 75: 10. Available from: https://doi.org/10.3322/caac.21871

Ref. 17. Surveillance Research Program. National Cancer Institute SEER*Stat software. version 9.0.41.4.

Ref. 18. Keegan THM, et al. (2024) J Clin Oncol, 42: 630. Available from: https://doi.org/10.1200/jco.23.01367

Ref. 19. Phillips SM, et al. (2015) Cancer Epidemiol Biomarkers Prev, 24: 653. Available from: https://doi.org/10.1158/1055-9965.EPI-14-1418

Ref. 20. Bhakta N, et al. (2017) Lancet, 390: 2569. Available from: https://doi.org/10.1016/S0140-6736(17)31610-0

Ref. 21. Bhatia S, et al. (2023) Jama, 330: 1175. Available from: https://doi.org/10.1001/jama.2023.16875

Ref. 22. Yeh JM, et al. (2020) JAMA Oncol, 6: 350. Available from: https://doi.org/10.1001/jamaoncol.2019.5582

Ref. 23. Ferrari A, et al. (2019) Eur J Cancer, 110: 120. Available from: https://doi.org/10.1016/j.ejca.2018.12.031

Ref. 24. National Cancer Institute. International Classification of Childhood Cancer (ICCC) – SEER Documentation. Accessed: August 31, 2025. Available from: https://seer.cancer.gov/iccc/index.html

Ref. 25. Chen X, et al. (2024) Nat Rev Cancer, 24: 382. Available from: https://doi.org/10.1038/s41568-024-00684-9

Ref. 26. Schultz KAP, et al. (2023) EJC Paediatr Oncol, 2. Available from: https://doi.org/10.1016/j.ejcped.2023.100024

Ref. 27. Wu D, et al. (2025) Pediatr Surg Int, 41: 84. Available from: https://doi.org/10.1007/s00383-025-05987-y

Ref. 28. Hoffman LM, et al. (2018) J Clin Oncol, 36: 1963. Available from: https://doi.org/10.1200/JCO.2017.75.9308

Ref. 29. Carceller F (2019) Transl Cancer Res, 8: 343. Available from: https://doi.org/10.21037/tcr.2019.03.12

Ref. 30. Pappo AS, et al. (2010) J Clin Oncol, 28: 5011. Available from: https://doi.org/10.1200/jco.2010.31.2603

Ref. 31. Poles GC, et al. (2016) J Pediatr Surg, 51: 1061. Available from: https://doi.org/10.1016/j.jpedsurg.2015.11.005

Ref. 32. Flores-Toro J, et al. (2025) J Natl Cancer Inst. Available from: https://doi.org/10.1093/jnci/djaf214

Ref. 33. Jagu S, et al. (2024) Pediatr Blood Cancer, 71: e30745. Available from: https://doi.org/10.1002/pbc.30745

Ref. 34. Foulkes I, et al. (2021) Cancer Discov, 11: 23. Available from: https://doi.org/10.1158/2159-8290.Cd-20-1657

Ref. 35. Goddard KAB, et al. (2025) JAMA Oncol, 11: 162. Available from: https://doi.org/10.1001/jamaoncol.2024.5381

Ref. 36. Brodeur GM, et al. (2025) Clin Cancer Res, 31: 2581. Available from: https://doi.org/10.1158/1078-0432.CCR-25-0423

Ref. 37. Roganovic J (2024) World J Clin Pediatr, 13: 95010. Available from: https://doi.org/10.5409/wjcp.v13.i3.95010

Ref. 38. Gallitto M, et al. (2019) Adv Radiat Oncol, 4: 520. Available from: https://doi.org/10.1016/j.adro.2019.03.009

Ref. 39. Kim HJ, et al. (2023) Cancer Res Treat, 55: 41. Available from: https://doi.org/10.4143/crt.2021.1514

Ref. 40. Arfè A, et al. (2023) J Natl Cancer Inst, 115: 917. Available from: https://doi.org/10.1093/jnci/djad082

Ref. 41. Cleveland C, et al. (2025) Lancet Child Adolesc Health, 9: 544. Available from: https://doi.org/10.1016/S2352-4642(25)00142-7

Ref. 42. Sondak VK, et al. (2024) Curr Oncol Rep, 26: 818. Available from: https://doi.org/10.1007/s11912-024-01542-5

Ref. 43. Chidiac C, et al. (2025) Pediatr Blood Cancer, 72: e31742. Available from: https://doi.org/10.1002/pbc.31742

Ref. 44. Lee SHR, et al. (2022) JAMA Oncol, 8: 354. Available from: https://doi.org/10.1001/jamaoncol.2021.6826

Ref. 45. Hashibe M, et al. (2025) Int J Cancer, 156: 1563. Available from: https://doi.org/10.1002/ijc.35259

Ref. 46. Preuss K, et al. (2025) Pediatr Blood Cancer, 72: e31520. Available from: https://doi.org/10.1002/pbc.31520

Ref. 47. Hymel E, et al. (2025) Cancer Epidemiol, 94: 102705. Available from: https://doi.org/10.1016/j.canep.2024.102705

Ref. 48. Asare M, et al. (2017) Oncol Nurs Forum, 44: 20. Available from: https://doi.org/10.1188/17.ONF.20-23

Ref. 49. Warnecke RB, et al. (2008) Am J Public Health, 98: 1608. Available from: https://doi.org/10.2105/AJPH.2006.102525

Ref. 50. Karvonen KA, et al. (2025) Cancer, 131: e35677. Available from: https://doi.org/10.1002/cncr.35677

Ref. 51. Winestone LE, et al. (2025) Cancer, 131: e35863. Available from: https://doi.org/10.1002/cncr.35863

Ref. 52. Ohlsen TJD, et al. (2023) Cancer Epidemiol Biomarkers Prev, 32: 141. Available from: https://doi.org/10.1158/1055-9965.Epi-22-0897

Ref. 53. Umaretiya PJ, et al. (2025) JAMA Netw Open, 8: e2458531. Available from: https://doi.org/10.1001/jamanetworkopen.2024.58531

Ref. 54. Nofi CP, et al. (2025) J Pediatr Surg, 60: 162216. Available from: https://doi.org/10.1016/j.jpedsurg.2025.162216

Ref. 55. Wolfson J, et al. (2014) J Natl Cancer Inst, 106: dju166. Available from: https://doi.org/10.1093/jnci/dju166

Ref. 56. Wolfson J, et al. (2017) Cancer Epidemiol Biomarkers Prev, 26: 312. Available from: https://doi.org/10.1158/1055-9965.EPI-16-0722

Ref. 57. Wolfson J, et al. (2014) Blood, 124: 556. Available from: https://doi.org/10.1182/blood.V124.21.556.556

Ref. 58. Wolfson JA, et al. (2023) J Natl Compr Canc Netw, 21: 881. Available from: https://doi.org/10.6004/jnccn.2023.7056

Ref. 59. Bona K, et al. (2014) J Pain Symptom Manage, 47: 594. Available from: https://doi.org/10.1016/j.jpainsymman.2013.04.003

Ref. 60. Bona K, et al. (2016) Pediatr Blood Cancer, 63: 105. Available from: https://doi.org/10.1002/pbc.25762

Ref. 61. Dussel V, et al. (2011) J Clin Oncol, 29: 1007. Available from: https://doi.org/10.1200/jco.2009.27.8960

Ref. 62. Environmental Protection Agency. NIEHS/EPA Children’s Environmental Health and Disease Prevention Research Centers Impact Report: Protecting Children’s Health Where They Live, Learn, and Play. Accessed: August 31, 2025. Available from: https://www.epa.gov/sites/production/files/2017-10/documents/niehs_epa_childrens_centers_impact_report_2017_0.pdf?pdf=chidrens-center-report

Ref. 63. Parsons SK, et al. (2023) J Clin Oncol, 41: 3260. Available from: https://doi.org/10.1200/JCO.22.01985

Ref. 64. Murray CJ (1994) Bull World Health Organ, 72: 429.

Ref. 65. Institute for Health Metrics and Evaluation. GBD Compare. Accessed: August 31, 2025. Available from: http://vizhub.healthdata.org/gbd-compare

Ref. 66. Atun R, et al. (2020) Lancet Oncol, 21: e185. Available from: https://doi.org/10.1016/s1470-2045(20)30022-x

Ref. 67. NIH’s Role in Sustraining the US Economy 2025 Update. Accessed: July 1, 2025. Available from: https://www.unitedformedicalresearch.org/wp-content/uploads/2025/03/UMR_NIH-Role-in-Sustaining-US-Economy-FY2024-2025-Update.pdf

Ref. 68. Hernádfoi MV, et al. (2024) JAMA Pediatr, 178: 548. Available from: https://doi.org/10.1001/jamapediatrics.2024.0642

Ref. 69. National Institutes of Health RePort. Funding for Various Research, Condition, and Disease Categories. Accessed: August 31, 2025. Available from: https://report.nih.gov/funding/categorical-spending#/

Ref. 70. Sertkaya A, et al. (2024) JAMA Netw Open, 7: e2415445. Available from: https://doi.org/10.1001/jamanetworkopen.2024.15445

Ref. 71. Sertkaya A, et al. (2016) Clin Trials, 13: 117. Available from: https://doi.org/10.1177/1740774515625964

Ref. 72. Unger JM, et al. (2024) J Clin Oncol, 42: 3917. Available from: https://doi.org/10.1200/JCO.24.00843

Ref. 73. Das S, et al. (2018) JAMA Oncol, 4: 1274. Available from: https://doi.org/10.1001/jamaoncol.2018.1739

Ref. 74. Addressing the Barriers to Pediatric Drug Development: Workshop Summary. Washington (DC)2008.

Ref. 75. Kearns GL, et al. (2003) N Engl J Med, 349: 1157. Available from: https://doi.org/10.1056/NEJMra035092

Ref. 76. McKinney RE, Jr. (2003) Pediatrics, 112: 669. Available from: https://doi.org/10.1542/peds.112.3.669

Ref. 77. Mackall CL, et al. (2024) Nat Med, 30: 1836. Available from: https://doi.org/10.1038/s41591-024-03035-1

Ref. 78. Hanahan D (2022) Cancer Discov, 12: 31. Available from: https://doi.org/10.1158/2159-8290.CD-21-1059

Ref. 79. Sweet-Cordero EA, et al. (2019) Science, 363: 1170. Available from: https://doi.org/10.1126/science.aaw3535

Ref. 80. Gore L, et al. (2024) Cell, 187: 1584. Available from: https://doi.org/10.1016/j.cell.2024.02.039

Ref. 81. Sharma A, et al. (2022) Nat Rev Cancer, 22: 593. Available from: https://doi.org/10.1038/s41568-022-00497-8

Ref. 82. Parsons DW, et al. (2016) JAMA Oncol, 2: 616. Available from: https://doi.org/10.1001/jamaoncol.2015.5699

Ref. 83. Wong M, et al. (2020) Nature Medicine, 26: 1742. Available from: https://doi.org/10.1038/s41591-020-1072-4

Ref. 84. Grobner SN, et al. (2018) Nature, 555: 321. Available from: https://doi.org/10.1038/nature25480

Ref. 85. Newman S, et al. (2021) Cancer Discov, 11: 3008. Available from: https://doi.org/10.1158/2159-8290.CD-20-1631

Ref. 86. Stoltze U, et al. (2025) Leukemia, 39: 1031. Available from: https://doi.org/10.1038/s41375-025-02535-4

Ref. 87. Kratz CP (2025) Nat Rev Cancer, 25: 109. Available from: https://doi.org/10.1038/s41568-024-00775-7

Ref. 88. Schurink B, et al. (2025) Virchows Arch, 486: 3. Available from: https://doi.org/10.1007/s00428-025-04029-1

Ref. 89. Zhang J, et al. (2015) N Engl J Med, 373: 2336. Available from: https://doi.org/10.1056/NEJMoa1508054

Ref. 90. Douglas SPM, et al. (2022) Sci Rep, 12: 10670. Available from: https://doi.org/10.1038/s41598-022-14364-x

Ref. 91. Kamihara J, et al. (2024) Clin Cancer Res, 30: 3137. Available from: https://doi.org/10.1158/1078-0432.CCR-24-0237

Ref. 92. Gillani R, et al. (2022) Am J Hum Genet, 109: 1026. Available from: https://doi.org/10.1016/j.ajhg.2022.04.007

Ref. 93. Taub JW, et al. (2017) Blood, 129: 3304. Available from: https://doi.org/10.1182/blood-2017-01-764324

Ref. 94. Shen Q, et al. (2025) Pediatr Blood Cancer, 72: e31569. Available from: https://doi.org/10.1002/pbc.31569

Ref. 95. Gillani R, et al. (2025) Science, 387: eadq0071. Available from: https://doi.org/10.1126/science.adq0071

Ref. 96. Oliver TRW, et al. (2025) Nat Genet, 57: 515. Available from: https://doi.org/10.1038/s41588-025-02097-2

Ref. 97. Thatikonda V, et al. (2023) Nat Cancer, 4: 276. Available from: https://doi.org/10.1038/s43018-022-00509-4

Ref. 98. Yang X, et al. (2024) Commun Biol, 7: 1630. Available from: https://doi.org/10.1038/s42003-024-07293-0

Ref. 99. Brady SW, et al. (2022) Nat Genet, 54: 1376. Available from: https://doi.org/10.1038/s41588-022-01159-z

Ref. 100. Polonen P, et al. (2024) Nature, 632: 1082. Available from: https://doi.org/10.1038/s41586-024-07807-0

Ref. 101. Liu SV, et al. (2025) Signal Transduct Target Ther, 10: 111. Available from: https://doi.org/10.1038/s41392-025-02161-7

Ref. 102. Wang’ondu RW, et al. (2025) Leukemia, 39: 1595. Available from: https://doi.org/10.1038/s41375-025-02633-3

Ref. 103. Bartolucci D, et al. (2022) Cancers (Basel), 14. Available from: https://doi.org/10.3390/cancers14184421

Ref. 104. Fernandez Garcia A, et al. (2025) Front Oncol, 15: 1584978. Available from: https://doi.org/10.3389/fonc.2025.1584978

Ref. 105. van Belzen I, et al. (2024) Cell Genom, 4: 100675. Available from: https://doi.org/10.1016/j.xgen.2024.100675

Ref. 106. Chen F, et al. (2025) Nat Commun, 16: 4713. Available from: https://doi.org/10.1038/s41467-025-60110-y

Ref. 107. International Agency for Cancer Research. Central Nervous System Tumours. Accessed: September 30, 2025. Available from: https://publications.iarc.who.int/601

Ref. 108. Schafer Hackenhaar F, et al. (2025) Blood, 145: 2161. Available from: https://doi.org/10.1182/blood.2024026027

Ref. 109. Steinicke TL, et al. (2025) Nat Genet, 57: 2456. Available from: https://doi.org/10.1038/s41588-025-02321-z

Ref. 110. Schonung M, et al. (2021) Clin Cancer Res, 27: 158. Available from: https://doi.org/10.1158/1078-0432.CCR-20-3184

Ref. 111. Jing J, et al. (2023) Signal Transduct Target Ther, 8: 315. Available from: https://doi.org/10.1038/s41392-023-01559-5

Ref. 112. Liu J, et al. (2022) Signal Transduct Target Ther, 7: 3. Available from: https://doi.org/10.1038/s41392-021-00762-6

Ref. 113. Shi Q, et al. (2024) Signal Transduct Target Ther, 9: 128. Available from: https://doi.org/10.1038/s41392-024-01828-x

Ref. 114. Morice S, et al. (2020) Cancers (Basel), 12. Available from: https://doi.org/10.3390/cancers12030645

Ref. 115. Ney GM, et al. (2020) Cancer Res, 80: 5155. Available from: https://doi.org/10.1158/0008-5472.CAN-20-0916

Ref. 116. Busico A, et al. (2024) Sci Rep, 14: 13138. Available from: https://doi.org/10.1038/s41598-024-64149-7

Ref. 117. Lagan E, et al. (2025) Mol Cell, 85: 2110. Available from: https://doi.org/10.1016/j.molcel.2025.04.026

Ref. 118. Barron T, et al. (2025) Nature, 639: 1060. Available from: https://doi.org/10.1038/s41586-024-08579-3

Ref. 119. Aoki T, et al. (2025) Front Oncol, 15: 1515250. Available from: https://doi.org/10.3389/fonc.2025.1515250

Ref. 120. Chen Q, et al. (2025) Cell, 188: 1425. Available from: https://doi.org/10.1016/j.cell.2024.12.014

Ref. 121. Yu W, et al. (2025) Nat Genet, 57: 1142. Available from: https://doi.org/10.1038/s41588-025-02158-6

Ref. 122. LaBelle JJ, et al. (2025) Cell Rep Med, 6: 102095. Available from: https://doi.org/10.1016/j.xcrm.2025.102095

Ref. 123. Callaway E (2024) Nature, 634: 525. Available from: https://doi.org/10.1038/d41586-024-03214-7

Ref. 124. Mumme HL, et al. (2025) Nat Commun, 16: 4114. Available from: https://doi.org/10.1038/s41467-025-59362-5

Ref. 125. Chen C, et al. (2025) Blood, 145: 2685. Available from: https://doi.org/10.1182/blood.2024027270

Ref. 126. Leo IR, et al. (2022) Nat Commun, 13: 1691. Available from: https://doi.org/10.1038/s41467-022-29224-5

Ref. 127. Chen C, et al. (2022) Blood, 139: 2198. Available from: https://doi.org/10.1182/blood.2021013442

Ref. 128. Xu J, et al. (2025) Nat Cancer, 6: 102. Available from: https://doi.org/10.1038/s43018-024-00863-5

Ref. 129. Iacobucci I, et al. (2025) Nat Cancer, 6: 1242. Available from: https://doi.org/10.1038/s43018-025-00987-2

Ref. 130. Xu Y, et al. (2025) Dev Cell. Available from: https://doi.org/10.1016/j.devcel.2025.04.013

Ref. 131. Okonechnikov K, et al. (2025) Nature, 642: 1062. Available from: https://doi.org/10.1038/s41586-025-08973-5

Ref. 132. Mardis ER (2025) Annu Rev Genomics Hum Genet, 26: 279. Available from: https://doi.org/10.1146/annurev-genom-120823-010156

Ref. 133. Randall MP, et al. (2024) J Natl Cancer Inst, 116: 138. Available from: https://doi.org/10.1093/jnci/djad182

Ref. 134. Dharia NV, et al. (2021) Nat Genet, 53: 529. Available from: https://doi.org/10.1038/s41588-021-00819-w

Ref. 135. Lee HM, et al. (2023) Nat Commun, 14: 7332. Available from: https://doi.org/10.1038/s41467-023-43134-0

Ref. 136. Amatruda JF (2021) Dis Model Mech, 14. Available from: https://doi.org/10.1242/dmm.048930

Ref. 137. Polak R, et al. (2024) Nat Rev Cancer, 24: 523. Available from: https://doi.org/10.1038/s41568-024-00706-6

Ref. 138. Kim SY, et al. (2025) Trends Cancer, 11: 665. Available from: https://doi.org/10.1016/j.trecan.2025.03.005

Ref. 139. van Tilburg CM, et al. (2020) BMC Cancer, 20: 523. Available from: https://doi.org/10.1186/s12885-020-07008-8

Ref. 140. Biswas K, et al. (2023) Cancer Sci, 114: 1800. Available from: https://doi.org/10.1111/cas.15737

Ref. 141. Schoof M, et al. (2023) Nat Commun, 14: 7717. Available from: https://doi.org/10.1038/s41467-023-43564-w

Ref. 142. Li Y, et al. (2025) Nat Commun, 16: 1091. Available from: https://doi.org/10.1038/s41467-024-54861-3

Ref. 143. National Cancer Institute. Division of Cancer Treatment & Diagnosis. NCI Pediatric Preclinical In Vivo Testing (PIVOT). Accessed: August 31, 2025. Available from: https://dctd.cancer.gov/research/networks/pediatric-pivot

Ref. 144. eClinicalMedicine (2024) EClinicalMedicine, 72: 102705. Available from: https://doi.org/10.1016/j.eclinm.2024.102705

Ref. 145. Wen S, et al. (2024) EJC Paediatric Oncology, 4: 100197. Available from: https://doi.org/10.1016/j.ejcped.2024.100197

Ref. 146. Thiesen A, et al. (2025) Cancer Research, 85: 2423. Available from: https://doi.org/10.1158/1538-7445.Am2025-2423

Ref. 147. Tak D, et al. (2025) NEJM AI, 2. Available from: https://doi.org/10.1056/aioa2400703

Ref. 148. Lebrun L, et al. (2025) Sci Rep, 15: 2857. Available from: https://doi.org/10.1038/s41598-025-87079-4

Ref. 149. Sturm D, et al. (2023) Nat Med, 29: 917. Available from: https://doi.org/10.1038/s41591-023-02255-1

Ref. 150. Koelsche C, et al. (2021) Nat Commun, 12: 498. Available from: https://doi.org/10.1038/s41467-020-20603-4

Ref. 151. Brandl B, et al. (2025) Nat Med, 31: 840. Available from: https://doi.org/10.1038/s41591-024-03435-3

Ref. 152. Patel A, et al. (2025) Nat Med, 31: 1567. Available from: https://doi.org/10.1038/s41591-025-03562-5

Ref. 153. Schaffer LV, et al. (2025) Nature, 642: 222. Available from: https://doi.org/10.1038/s41586-025-08878-3

Ref. 154. Lei S, et al. (2025) Leukemia, 39: 420. Available from: https://doi.org/10.1038/s41375-024-02461-x

Ref. 155. Madanat-Harjuoja LM, et al. (2022) J Clin Oncol, 40: 3047. Available from: https://doi.org/10.1200/JCO.22.00098

Ref. 156. Escudero L, et al. (2020) Nat Commun, 11: 5376. Available from: https://doi.org/10.1038/s41467-020-19175-0

Ref. 157. Liu APY, et al. (2021) Cancer Cell, 39: 1519. Available from: https://doi.org/10.1016/j.ccell.2021.09.012

Ref. 158. Bonner ER, et al. (2018) NPJ Precis Oncol, 2: 29. Available from: https://doi.org/10.1038/s41698-018-0072-z

Ref. 159. Bosse KR, et al. (2022) Cancer Discov, 12: 2800. Available from: https://doi.org/10.1158/2159-8290.CD-22-0287

Ref. 160. Janssen FW, et al. (2024) NPJ Precis Oncol, 8: 172. Available from: https://doi.org/10.1038/s41698-024-00657-z

Ref. 161. de Bruijn I, et al. (2025) Nat Methods, 22: 664. Available from: https://doi.org/10.1038/s41592-025-02643-0

Ref. 162. Sussman JH, et al. (2024) bioRxiv. Available from: https://doi.org/10.1101/2024.03.06.583588

Ref. 163. Parsons DW, et al. (2022) J Clin Oncol, 40: 2224. Available from: https://doi.org/10.1200/jco.21.02838

Ref. 164. Ma X, et al. (2018) Nature, 555: 371. Available from: https://doi.org/10.1038/nature25795

Ref. 165. Goudie C, et al. (2021) JAMA Oncol, 7: 1806. Available from: https://doi.org/10.1001/jamaoncol.2021.4536

Ref. 166. Legius E, et al. (2021) Genet Med, 23: 1506. Available from: https://doi.org/10.1038/s41436-021-01170-5

Ref. 167. Kim JW (2025) J Korean Neurosurg Soc, 68: 350. Available from: https://doi.org/10.3340/jkns.2025.0011

Ref. 168. Kuhlen M, et al. (2025) World J Pediatr, 21: 131. Available from: https://doi.org/10.1007/s12519-024-00853-8

Ref. 169. Alonso-Luna O, et al. (2023) Ann Hum Genet, 87: 81. Available from: https://doi.org/10.1111/ahg.12502

Ref. 170. Bakhuizen JJ, et al. (2024) Lancet Child Adolesc Health, 8: 751. Available from: https://doi.org/10.1016/S2352-4642(24)00144-5

Ref. 171. Capasso A, et al. (2025) J Genet Couns, 34: e1887. Available from: https://doi.org/10.1002/jgc4.1887

Ref. 172. Zion TN, et al. (2023) Genet Med, 25: 100020. Available from: https://doi.org/10.1016/j.gim.2023.100020

Ref. 173. Droin-Mollard M, et al. (2024) Eur J Hum Genet, 32: 1446. Available from: https://doi.org/10.1038/s41431-024-01653-4

Ref. 174. Dusic EJ, et al. (2022) Front Digit Health, 4: 961128. Available from: https://doi.org/10.3389/fdgth.2022.961128

Ref. 175. Rapoport CS, et al. (2024) Cancer Rep (Hoboken), 7: e2119. Available from: https://doi.org/10.1002/cnr2.2119

Ref. 176. Venier RE, et al. (2022) J Genet Couns, 31: 901. Available from: https://doi.org/10.1002/jgc4.1559

Ref. 177. Jacobs MF, et al. (2024) JCO Precis Oncol, 8: e2300539. Available from: https://doi.org/10.1200/PO.23.00539

Ref. 178. Greene BL, et al. (2024) Front Oncol, 14: 1338022. Available from: https://doi.org/10.3389/fonc.2024.1338022

Ref. 179. Howard Sharp KM, et al. (2020) JCO Precis Oncol, 4: 202. Available from: https://doi.org/10.1200/PO.19.00213

Ref. 180. Vuocolo B, et al. (2024) J Genet Couns, 33: 1337. Available from: https://doi.org/10.1002/jgc4.1858

Ref. 181. Yeh JM, et al. (2021) Genet Med, 23: 1366. Available from: https://doi.org/10.1038/s41436-021-01124-x

Ref. 182. Smith HS, et al. (2024) Am J Hum Genet, 111: 2094. Available from: https://doi.org/10.1016/j.ajhg.2024.08.011

Ref. 183. Linga BG, et al. (2024) Cancers (Basel), 16. Available from: https://doi.org/10.3390/cancers16112017

Ref. 184. Kunst N, et al. (2022) J Natl Cancer Inst, 114: 722. Available from: https://doi.org/10.1093/jnci/djac013

Ref. 185. Genomics England. Newborn Genomes Programme. Accessed: August 31, 2025. Available from: https://www.genomicsengland.co.uk/initiatives/newborns

Ref. 186. Zelley K, et al. (2024) Clin Cancer Res, 30: 3983. Available from: https://doi.org/10.1158/1078-0432.CCR-24-1165

Ref. 187. Westdorp H, et al. (2017) Cancer Lett, 403: 159. Available from: https://doi.org/10.1016/j.canlet.2017.06.018

Ref. 188. Henderson JJ, et al. (2022) JCO Precis Oncol, 6: e2100286. Available from: https://doi.org/10.1200/PO.21.00286

Ref. 189. Palova H, et al. (2024) NPJ Precis Oncol, 8: 110. Available from: https://doi.org/10.1038/s41698-024-00597-8

Ref. 190. Villani A, et al. (2016) Lancet Oncol, 17: 1295. Available from: https://doi.org/10.1016/S1470-2045(16)30249-2

Ref. 191. Patel N, et al. (2023) J Neurosurg Pediatr, 31: 258. Available from: https://doi.org/10.3171/2022.12.PEDS22261

Ref. 192. Tewattanarat N, et al. (2022) Pediatr Radiol, 52: 1283. Available from: https://doi.org/10.1007/s00247-022-05296-9

Ref. 193. Greer MC, et al. (2024) Clin Cancer Res, 30: 5021. Available from: https://doi.org/10.1158/1078-0432.CCR-24-1374

Ref. 194. Hansford JR, et al. (2024) Clin Cancer Res, 30: 2342. Available from: https://doi.org/10.1158/1078-0432.CCR-23-4033

Ref. 195. Danylchuk NR, et al. (2021) J Genet Couns, 30: 1361. Available from: https://doi.org/10.1002/jgc4.1481

Ref. 196. Ganguly S, et al. (2025) Pediatr Blood Cancer, 72: e31552. Available from: https://doi.org/10.1002/pbc.31552

Ref. 197. Bakhuizen JJ, et al. (2024) EJC Paediatric Oncology, 4: 100176. Available from: https://doi.org/10.1016/j.ejcped.2024.100176

Ref. 198. Van Hoyweghen S, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17030517

Ref. 199. Finney J, et al. (2025) J Genet Couns, 34: e1982. Available from: https://doi.org/10.1002/jgc4.1982

Ref. 200. Green S, et al. (2023) J Genet Couns, 32: 4. Available from: https://doi.org/10.1002/jgc4.1627

Ref. 201. Kaffai S, et al. (2024) Front Pediatr, 12: 1410061. Available from: https://doi.org/10.3389/fped.2024.1410061

Ref. 202. Pan V, et al. (2025) J Genet Couns, 34: e70051. Available from: https://doi.org/10.1002/jgc4.70051

Ref. 203. Jenkins SM, et al. (2025) Pediatr Res, 97: 1261. Available from: https://doi.org/10.1038/s41390-025-03859-8

Ref. 204. Orbach D, et al. (2023) EJC Paediatric Oncology, 2: 100023. Available from: https://doi.org/10.1016/j.ejcped.2023.100023

Ref. 205. MacFarland SP, et al. (2019) JCO Precis Oncol, 3. Available from: https://doi.org/10.1200/po.19.00062

Ref. 206. Brzezinski JJ, et al. (2025) Clin Cancer Res, 31: 18. Available from: https://doi.org/10.1158/1078-0432.CCR-24-2488

Ref. 207. Blake A, et al. (2024) JAMA Oncol, 10: 1060. Available from: https://doi.org/10.1001/jamaoncol.2024.1878

Ref. 208. Apps J, et al. (2024) EJC Paediatric Oncology, 4: 100191. Available from: https://doi.org/10.1016/j.ejcped.2024.100191

Ref. 209. National Comprehensive Cancer Network. NCCN Guidlines. Accessed: August 31, 2025. Available from: https://www.nccn.org/guidelines/category_2

Ref. 210. National Institute for Health and Care Excellence. NICE guidance. Accessed: August 31, 2025. Available from: https://www.nice.org.uk/guidance

Ref. 211. National Society of Geentic Counselors. NSGC Practice Guidelines. Accessed: August 31, 2025. Available from: https://www.nsgc.org/Research-and-Publications/Practice-Guidelines

Ref. 212. International Society of Paediatric Oncology (SIOP). European Standards of Care for Children with Cancer. Accessed: August 31, 2025. Available from: https://siope.eu/media/wp-content/uploads/2013/09/European_Standards_final_2011.pdf

Ref. 213. Frebourg T, et al. (2020) Eur J Hum Genet, 28: 1379. Available from: https://doi.org/10.1038/s41431-020-0638-4

Ref. 214. Brioude F, et al. (2018) Nat Rev Endocrinol, 14: 229. Available from: https://doi.org/10.1038/nrendo.2017.166

Ref. 215. Brodeur GM, et al. (2017) Clin Cancer Res, 23: e1. Available from: https://doi.org/10.1158/1078-0432.Ccr-17-0702

Ref. 216. Rednam SP, et al. (2025) Clin Cancer Res, 31: 3368. Available from: https://doi.org/10.1158/1078-0432.CCR-24-4354

Ref. 217. Wasserman JD, et al. (2025) Clin Cancer Res, 31: 3628. Available from: https://doi.org/10.1158/1078-0432.CCR-24-3860

Ref. 218. Voss SD, et al. (2025) Clin Cancer Res, 31: 3638. Available from: https://doi.org/10.1158/1078-0432.CCR-25-0597

Ref. 219. Rednam SP, et al. (2025) Clin Cancer Res, 31: 2271. Available from: https://doi.org/10.1158/1078-0432.CCR-24-3525

Ref. 220. Achatz MI, et al. (2025) Clin Cancer Res, 31: 1831. Available from: https://doi.org/10.1158/1078-0432.CCR-24-3301

Ref. 221. Kamihara J, et al. (2025) Clin Cancer Res, 31: 1573. Available from: https://doi.org/10.1158/1078-0432.CCR-24-3271

Ref. 222. Perrino MR, et al. (2025) Clin Cancer Res, 31: 1400. Available from: https://doi.org/10.1158/1078-0432.CCR-24-3278

Ref. 223. Michaeli O, et al. (2025) Clin Cancer Res, 31: 457. Available from: https://doi.org/10.1158/1078-0432.CCR-24-2171

Ref. 224. Schultz KAP, et al. (2025) Clin Cancer Res, 31: 234. Available from: https://doi.org/10.1158/1078-0432.CCR-24-1947

Ref. 225. Kalish JM, et al. (2024) Clin Cancer Res, 30: 5260. Available from: https://doi.org/10.1158/1078-0432.CCR-24-2100

Ref. 226. Nakano Y, et al. (2024) Clin Cancer Res, 30: 5009. Available from: https://doi.org/10.1158/1078-0432.CCR-24-1098

Ref. 227. Perrino MR, et al. (2024) Clin Cancer Res, 30: 4834. Available from: https://doi.org/10.1158/1078-0432.CCR-24-1611

Ref. 228. MacFarland SP, et al. (2024) Clin Cancer Res, 30: 4566. Available from: https://doi.org/10.1158/1078-0432.CCR-24-0953

Ref. 229. Maese LD, et al. (2024) Clin Cancer Res, 30: 4286. Available from: https://doi.org/10.1158/1078-0432.CCR-24-0685

Ref. 230. Das A, et al. (2024) Clin Cancer Res, 30: 3378. Available from: https://doi.org/10.1158/1078-0432.CCR-23-3994

Ref. 231. Kratz CP, et al. (2024) Clin Cancer Res, 30: 1733. Available from: https://doi.org/10.1158/1078-0432.CCR-23-3683

Ref. 232. Bosch de Basea M, et al. (2023) Nat Med, 29: 3111. Available from: https://doi.org/10.1038/s41591-023-02620-0

Ref. 233. Smith-Bindman R, et al. (2025) N Engl J Med, 393: 1269. Available from: https://doi.org/10.1056/NEJMoa2502098

Ref. 234. Sundby RT, et al. (2022) Curr Opin Pediatr, 34: 39. Available from: https://doi.org/10.1097/MOP.0000000000001088

Ref. 235. Janssen FW, et al. (2024) NPJ Precis Oncol, 8: 210. Available from: https://doi.org/10.1038/s41698-024-00677-9

Ref. 236. Sundby RT, et al. (2024) Clin Cancer Res, 30: 4363. Available from: https://doi.org/10.1158/1078-0432.CCR-24-0797

Ref. 237. Wong D, et al. (2024) Cancer Discov, 14: 104. Available from: https://doi.org/10.1158/2159-8290.CD-23-0456

Ref. 238. Farncombe KM, et al. (2023) Am J Hum Genet, 110: 1616. Available from: https://doi.org/10.1016/j.ajhg.2023.08.014

Ref. 239. Wong D, et al. (2024) Nat Commun, 15: 7386. Available from: https://doi.org/10.1038/s41467-024-51529-w

Ref. 240. ClinicalTrials.gov. Study Details | NCT06726642 | CfDNA in Hereditary And High-risk Malignancies 2 | ClinicalTrials.gov. Accessed: October 17, 2025. Available from: https://clinicaltrials.gov/study/NCT06726642

Ref. 241. EDISYN. About – Early Detection in Syndromic Cancers. Accessed: Available from: https://edisyn.org/about/

Ref. 242. Imai M, et al. (2025) Int J Clin Oncol, 30: 180. Available from: https://doi.org/10.1007/s10147-025-02694-5

Ref. 243. Rubinstein WS, et al. (2024) CA Cancer J Clin, 74: 368. Available from: https://doi.org/10.3322/caac.21833

Ref. 244. Wade R, et al. (2025) Health Technol Assess, 29: 1. Available from: https://doi.org/10.3310/DLMT1294

Ref. 245. Doculara L, et al. (2022) Front Mol Biosci, 9: 885597. Available from: https://doi.org/10.3389/fmolb.2022.885597

Ref. 246. Izquierdo E, et al. (2021) Neurooncol Adv, 3: vdab013. Available from: https://doi.org/10.1093/noajnl/vdab013

Ref. 247. Crotty EE, et al. (2024) Neurooncol Adv, 6: vdae126. Available from: https://doi.org/10.1093/noajnl/vdae126

Ref. 248. Rahmqvist I, et al. (2024) Biomark Res, 12: 148. Available from: https://doi.org/10.1186/s40364-024-00688-5

Ref. 249. Hashem H, et al. (2025) Front Med (Lausanne), 12: 1555893. Available from: https://doi.org/10.3389/fmed.2025.1555893

Ref. 250. Elsayid NN, et al. (2025) Cureus, 17: e77524. Available from: https://doi.org/10.7759/cureus.77524

Ref. 251. Ramesh S, et al. (2021) JCO Clin Cancer Inform, 5: 1208. Available from: https://doi.org/10.1200/CCI.21.00102

Ref. 252. Hassan M, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17111828

Ref. 253. Kanukollu VM, et al. Leukocoria. StatPearls. Treasure Island (FL)2025.

Ref. 254. Global Retinoblastoma Study G, et al. (2020) JAMA Oncol, 6: 685. Available from: https://doi.org/10.1001/jamaoncol.2019.6716

Ref. 255. Kaur K, et al. Retinoblastoma. StatPearls. Treasure Island (FL)2025.

Ref. 256. Munson MC, et al. (2019) Sci Adv, 5: eaax6363. Available from: https://doi.org/10.1126/sciadv.aax6363

Ref. 257. Bernard A, et al. (2022) Ophthalmol Sci, 2: 100158. Available from: https://doi.org/10.1016/j.xops.2022.100158

Ref. 258. Aldughayfiq B, et al. (2023) Diagnostics (Basel), 13. Available from: https://doi.org/10.3390/diagnostics13111932

Ref. 259. Subasri V, et al. (2025) Nat Commun, 16: 7976. Available from: https://doi.org/10.1038/s41467-025-62894-5

Ref. 260. Perrino M, et al. (2025) AJR Am J Roentgenol. Available from: https://doi.org/10.2214/AJR.25.32735

Ref. 261. Grasparil AD, 2nd, et al. (2020) AJR Am J Roentgenol, 215: 1002. Available from: https://doi.org/10.2214/AJR.19.22399

Ref. 262. Murphy AJ, et al. (2023) Front Pediatr, 11: 1122390. Available from: https://doi.org/10.3389/fped.2023.1122390

Ref. 263. Mussa A, et al. (2019) J Cancer Res Clin Oncol, 145: 3115. Available from: https://doi.org/10.1007/s00432-019-03038-3

Ref. 264. Papageorgiou E, et al. (2022) Expert Review of Ophthalmology, 17: 87. Available from: https://doi.org/10.1080/17469899.2022.2060821

Ref. 265. Allphin MT, et al. (2024) Fam Cancer, 24: 12. Available from: https://doi.org/10.1007/s10689-024-00424-w

Ref. 266. Mobley EM, et al. (2023) Cancer Med, 12: 18281. Available from: https://doi.org/10.1002/cam4.6426

Ref. 267. Butler E, et al. (2021) CA Cancer J Clin, 71: 315. Available from: https://doi.org/10.3322/caac.21665

Ref. 268. Hodder A, et al. (2024) Nat Med: s41591. Available from: https://doi.org/10.1038/s41591-024-03056-w

Ref. 269. Helms L, et al. (2023) Pediatrics, 152: e2023061539. Available from: https://doi.org/10.1542/peds.2023-061539

Ref. 270. Neel DV, et al. (2020) Cancer Med, 9: 4495. Available from: https://doi.org/10.1002/cam4.3083

Ref. 271. Unger JM, et al. (2024) J Clin Oncol, 42: 2139. Available from: https://doi.org/10.1200/JCO.23.01030

Ref. 272. Fashoyin-Aje LA, et al. (2024) JAMA Oncol, 10: 380. Available from: https://doi.org/10.1001/jamaoncol.2023.5781

Ref. 273. Faulk KE, et al. (2020) PLoS One, 15: e0230824. Available from: https://doi.org/10.1371/journal.pone.0230824

Ref. 274. Wyatt KD, et al. (2024) JCO Oncol Pract, 20: 603. Available from: https://doi.org/10.1200/op.23.00826

Ref. 275. Monroe C, et al. (2025) Pediatr Blood Cancer, 72: e31641. Available from: https://doi.org/10.1002/pbc.31641

Ref. 276. Neel DV, et al. (2019) Eur J Cancer, 112: 49. Available from: https://doi.org/10.1016/j.ejca.2019.02.011

Ref. 277. Forrest SJ, et al. (2018) Curr Opin Pediatr, 30: 17. Available from: https://doi.org/10.1097/mop.0000000000000570

Ref. 278. Drilon A, et al. (2018) N Engl J Med, 378: 731. Available from: https://doi.org/10.1056/NEJMoa1714448

Ref. 279. Cuglievan B, et al. (2025) Nature Reviews Clinical Oncology, 22: 155. Available from: https://doi.org/10.1038/s41571-025-00989-0

Ref. 280. Khan T, et al. (2019) Ther Innov Regul Sci, 53: 270. Available from: https://doi.org/10.1177/2168479018774533

Ref. 281. Bautista F, et al. (2024) J Clin Oncol, 42: 2516. Available from: https://doi.org/10.1200/jco.23.01237

Ref. 282. Greenzang KA, et al. (2025) JNCI: Journal of the National Cancer Institute. Available from: https://doi.org/10.1093/jnci/djaf083

Ref. 283. Riedl D, et al. (2024) EJC Paediatric Oncology, 4. Available from: https://doi.org/10.1016/j.ejcped.2024.100199

Ref. 284. Foote HP, et al. (2024) J Pediatr Pharmacol Ther, 29: 336. Available from: https://doi.org/10.5863/1551-6776-29.3.336

Ref. 285. Lawrence W. History of Surgical Oncology. In: Norton JA, Barie PS, Bollinger RR, Chang AE, Lowry SF, Mulvihill SJ, et al., editors. Surgery. New York, NY: Springer New York; 2008. p 1889.

Ref. 286. Gianfaldoni S, et al. (2017) Open Access Maced J Med Sci, 5: 521. Available from: https://doi.org/10.3889/oamjms.2017.122

Ref. 287. DeVita VT, Jr., et al. (2008) Cancer Res, 68: 8643. Available from: https://doi.org/10.1158/0008-5472.CAN-07-6611

Ref. 288. Dobashi Y, et al. (2012) Chemotherapy, 1: 2.

Ref. 289. Zhang Y, et al. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology. Volume 172020.

Ref. 290. Sánchez-Guixé M, et al. (2024) Cancer Discovery, 14: 953. Available from: https://doi.org/10.1158/2159-8290.Cd-23-1186

Ref. 291. Jeha S, et al. (2019) J Clin Oncol, 37: 3377. Available from: https://doi.org/10.1200/jco.19.01692

Ref. 292. Pui CH, et al. (2009) N Engl J Med, 360: 2730. Available from: https://doi.org/10.1056/NEJMoa0900386

Ref. 293. Dix DB, et al. (2018) J Clin Oncol, 36: 1564. Available from: https://doi.org/10.1200/JCO.2017.77.1931

Ref. 294. Friedman DL, et al. (2014) J Clin Oncol, 32: 3651. Available from: https://doi.org/10.1200/jco.2013.52.5410

Ref. 295. Mauz-Körholz C, et al. (2022) Lancet Oncol, 23: 125. Available from: https://doi.org/10.1016/s1470-2045(21)00470-8

Ref. 296. Corrigan KL, et al. (2025) Cancer Epidemiol Biomarkers Prev, 34: 1483. Available from: https://doi.org/10.1158/1055-9965.EPI-25-0049

Ref. 297. Katzenstein HM, et al. (2019) Lancet Oncol, 20: 719. Available from: https://doi.org/10.1016/s1470-2045(18)30895-7

Ref. 298. Spunt SL, et al. (2024) Cancer, 130: 2683. Available from: https://doi.org/10.1002/cncr.35305

Ref. 299. Wijnen MWH, et al. (2021) Surg Oncol Clin N Am, 30: 417. Available from: https://doi.org/10.1016/j.soc.2020.11.008

Ref. 300. Phelps HM, et al. (2018) Children (Basel), 5. Available from: https://doi.org/10.3390/children5120158

Ref. 301. Upadhyay R, et al. (2024) Cancers (Basel), 16. Available from: https://doi.org/10.3390/cancers16203530

Ref. 302. Casey DL, et al. (2025) Practical Radiation Oncology, 15: 180. Available from: https://doi.org/10.1016/j.prro.2024.10.004

Ref. 303. Dunsmore KP, et al. (2020) J Clin Oncol, 38: 3282. Available from: https://doi.org/10.1200/JCO.20.00256

Ref. 304. Mardis ER (2024) Curr Opin Pediatr, 36: 71. Available from: https://doi.org/10.1097/mop.0000000000001311

Ref. 305. Mody RJ, et al. (2015) Jama, 314: 913. Available from: https://doi.org/10.1001/jama.2015.10080

Ref. 306. Forrest SJ, et al. (2024) Nature Communications, 15: 5837. Available from: https://doi.org/10.1038/s41467-024-49944-0

Ref. 307. Villani A, et al. (2023) Nature Cancer, 4: 203. Available from: https://doi.org/10.1038/s43018-022-00474-y

Ref. 308. van Tilburg CM, et al. (2021) Cancer Discov, 11: 2764. Available from: https://doi.org/10.1158/2159-8290.CD-21-0094

Ref. 309. Flores-Toro JA, et al. (2023) J Clin Oncol, 41: 4045. Available from: https://doi.org/10.1200/jco.22.02208

Ref. 310. Berlanga P, et al. (2022) Cancer Discov, 12: 1266. Available from: https://doi.org/10.1158/2159-8290.Cd-21-1136

Ref. 311. Geoerger B, et al. (2024) Eur J Cancer, 208: 114201. Available from: https://doi.org/10.1016/j.ejca.2024.114201

Ref. 312. Inaba H, et al. (2020) Haematologica, 105: 2524. Available from: https://doi.org/10.3324/haematol.2020.247031

Ref. 313. Chang TC, et al. (2024) J Clin Oncol, 42: 3491. Available from: https://doi.org/10.1200/JCO.23.02238

Ref. 314. Horbinski C, et al. (2025) JAMA Oncol, 11: 317. Available from: https://doi.org/10.1001/jamaoncol.2024.5506

Ref. 315. Northcott PA, et al. (2017) Nature, 547: 311. Available from: https://doi.org/10.1038/nature22973

Ref. 316. (2025) Neuro-Oncology. Available from: https://doi.org/10.1093/neuonc/noaf150

Ref. 317. Bagatell R, et al. (2023) Pediatr Blood Cancer, 70 Suppl 6: e30572. Available from: https://doi.org/10.1002/pbc.30572

Ref. 318. Moorman AV, et al. (2022) J Clin Oncol, 40: 4228. Available from: https://doi.org/10.1200/jco.22.00245

Ref. 319. Christodoulou E, et al. (2023) npj Precision Oncology, 7: 21. Available from: https://doi.org/10.1038/s41698-023-00357-0

Ref. 320. Shulman DS, et al. (2018) British Journal of Cancer, 119: 615. Available from: https://doi.org/10.1038/s41416-018-0212-9

Ref. 321. Panditharatna E, et al. (2018) Clin Cancer Res, 24: 5850. Available from: https://doi.org/10.1158/1078-0432.CCR-18-1345

Ref. 322. Zettler ME (2023) EJC Paediatric Oncology, 1. Available from: https://doi.org/10.1016/j.ejcped.2023.100005

Ref. 323. O’Brien MM, et al. (2022) J Clin Oncol, 40: 956. Available from: https://doi.org/10.1200/jco.21.01693

Ref. 324. Cerchione C, et al. (2021) Front Oncol, 11: 632231. Available from: https://doi.org/10.3389/fonc.2021.632231

Ref. 325. Murphy L, et al. (2023) Lancet Haematol, 10: e479. Available from: https://doi.org/10.1016/s2352-3026(23)00095-9

Ref. 326. Athale U, et al. (2019) Pediatr Blood Cancer, 66: e27827. Available from: https://doi.org/10.1002/pbc.27827

Ref. 327. Issa GC, et al. (2023) Nature, 615: 920. Available from: https://doi.org/10.1038/s41586-023-05812-3

Ref. 328. Yokoyama A, et al. (2005) Cell, 123: 207. Available from: https://doi.org/10.1016/j.cell.2005.09.025

Ref. 329. Issa GC, et al. (2025) J Clin Oncol, 43: 75. Available from: https://doi.org/10.1200/JCO.24.00826

Ref. 330. Kuhn MW, et al. (2016) Cancer Discov, 6: 1166. Available from: https://doi.org/10.1158/2159-8290.CD-16-0237

Ref. 331. Issa GC, et al. (2021) Leukemia, 35: 2482. Available from: https://doi.org/10.1038/s41375-021-01309-y

Ref. 332. Borkin D, et al. (2015) Cancer Cell, 27: 589. Available from: https://doi.org/10.1016/j.ccell.2015.02.016

Ref. 333. Garber K (2024) Nat Rev Drug Discov, 23: 567. Available from: https://doi.org/10.1038/d41573-024-00106-3

Ref. 334. ClinicalTrials.gov. Study Details | NCT06177067 | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia. Accessed: October 1, 2025. Available from: https://clinicaltrials.gov/study/NCT06177067

Ref. 335. US Food and Drug Administration. FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. Accessed: October 1, 2025. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation

Ref. 336. ClinicalTrials.gov. Study Details | NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia. Accessed: October 1, 2025. Available from: https://clinicaltrials.gov/study/NCT04067336

Ref. 337. Ziemin-van der Poel S, et al. (1991) Proc Natl Acad Sci U S A, 88: 10735. Available from: https://doi.org/10.1073/pnas.88.23.10735

Ref. 338. Gu Y, et al. (1992) Cell, 71: 701. Available from: https://doi.org/10.1016/0092-8674(92)90603-a

Ref. 339. Tkachuk DC, et al. (1992) Cell, 71: 691. Available from: https://doi.org/10.1016/0092-8674(92)90602-9

Ref. 340. Domer PH, et al. (1993) Proc Natl Acad Sci U S A, 90: 7884. Available from: https://doi.org/10.1073/pnas.90.16.7884

Ref. 341. Yu BD, et al. (1995) Nature, 378: 505. Available from: https://doi.org/10.1038/378505a0

Ref. 342. Corral J, et al. (1996) Cell, 85: 853. Available from: https://doi.org/10.1016/s0092-8674(00)81269-6

Ref. 343. Lavau C, et al. (1997) EMBO J, 16: 4226. Available from: https://doi.org/10.1093/emboj/16.14.4226

Ref. 344. Hughes CM, et al. (2004) Molecular Cell, 13: 587. Available from: https://doi.org/10.1016/S1097-2765(04)00081-4

Ref. 345. Yokoyama A, et al. (2004) Molecular and Cellular Biology, 24: 5639. Available from: https://doi.org/10.1128/MCB.24.13.5639-5649.2004

Ref. 346. Grembecka J, et al. (2010) Journal of Biological Chemistry, 285: 40690. Available from: https://doi.org/10.1074/jbc.M110.172783

Ref. 347. Shi A, et al. (2012) Blood, 120: 4461. Available from: https://doi.org/10.1182/blood-2012-05-429274

Ref. 348. Grembecka J, et al. (2012) Nature Chemical Biology, 8: 277. Available from: https://doi.org/10.1038/nchembio.773

Ref. 349. Uckelmann HJ, et al. (2023) Cancer Discovery, 13: 746. Available from: https://doi.org/10.1158/2159-8290.Cd-22-0366

Ref. 350. Aldoss I, et al. (2023) Blood, 142: LBA. Available from: https://doi.org/10.1182/blood-2023-192042

Ref. 351. Perner F, et al. (2023) Nature, 615: 913. Available from: https://doi.org/10.1038/s41586-023-05755-9

Ref. 352. Pollard JA, et al. (2016) J Clin Oncol, 34: 747. Available from: https://doi.org/10.1200/jco.2015.62.6846

Ref. 353. Gamis AS, et al. (2014) J Clin Oncol, 32: 3021. Available from: https://doi.org/10.1200/jco.2014.55.3628

Ref. 354. US Food and Drug Administration. FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients. Accessed: September 30, 2025. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-gemtuzumab-ozogamicin-cd33-positive-aml-pediatric-patients

Ref. 355. Castellino SM, et al. (2022) N Engl J Med, 387: 1649. Available from: https://doi.org/10.1056/NEJMoa2206660

Ref. 356. Lowe EJ, et al. (2023) J Clin Oncol, 41: 2043. Available from: https://doi.org/10.1200/JCO.22.00272

Ref. 357. Fangusaro J, et al. (2024) Neuro Oncol, 26: 25. Available from: https://doi.org/10.1093/neuonc/noad195

Ref. 358. Bouffet E, et al. (2023) N Engl J Med, 389: 1108. Available from: https://doi.org/10.1056/NEJMoa2303815

Ref. 359. Hargrave DR, et al. (2023) J Clin Oncol, 41: 5174. Available from: https://doi.org/10.1200/jco.23.00558

Ref. 360. Kilburn LB, et al. (2024) Nat Med, 30: 207. Available from: https://doi.org/10.1038/s41591-023-02668-y

Ref. 361. van Tilburg CM, et al. (2024) BMC Cancer, 24: 147. Available from: https://doi.org/10.1186/s12885-024-11820-x

Ref. 362. Molinaro AM, et al. (2019) Nature Reviews Neurology, 15: 405. Available from: https://doi.org/10.1038/s41582-019-0220-2

Ref. 363. Dang L, et al. (2009) Nature, 462: 739. Available from: https://doi.org/10.1038/nature08617

Ref. 364. Duncan CG, et al. (2012) Genome Res, 22: 2339. Available from: https://doi.org/10.1101/gr.132738.111

Ref. 365. Koivunen P, et al. (2012) Nature, 483: 484. Available from: https://doi.org/10.1038/nature10898

Ref. 366. Turcan S, et al. (2012) Nature, 483: 479. Available from: https://doi.org/10.1038/nature10866

Ref. 367. Mellinghoff IK, et al. (2023) Nat Med, 29: 615. Available from: https://doi.org/10.1038/s41591-022-02141-2

Ref. 368. Mellinghoff IK, et al. (2023) N Engl J Med, 389: 589. Available from: https://doi.org/10.1056/NEJMoa2304194

Ref. 369. Venneti S, et al. (2023) Cancer Discov, 13: 2370. Available from: https://doi.org/10.1158/2159-8290.Cd-23-0131

Ref. 370. Arrillaga-Romany I, et al. (2024) J Clin Oncol, 42: 1542. Available from: https://doi.org/10.1200/jco.23.01134

Ref. 371. Majzner RG, et al. (2022) Nature, 603: 934. Available from: https://doi.org/10.1038/s41586-022-04489-4

Ref. 372. Monje M, et al. (2025) Nature, 637: 708. Available from: https://doi.org/10.1038/s41586-024-08171-9

Ref. 373. Oesterheld J, et al. (2024) J Clin Oncol, 42: 90. Available from: https://doi.org/10.1200/JCO.22.02875

Ref. 374. Moertel CL, et al. (2025) J Clin Oncol, 43: 716. Available from: https://doi.org/10.1200/JCO.24.01034

Ref. 375. Dombi E, et al. (2016) N Engl J Med, 375: 2550. Available from: https://doi.org/10.1056/NEJMoa1605943

Ref. 376. Gross AM, et al. (2023) Neuro Oncol, 25: 1883. Available from: https://doi.org/10.1093/neuonc/noad086

Ref. 377. Gounder M, et al. (2020) Lancet Oncol, 21: 1423. Available from: https://doi.org/10.1016/s1470-2045(20)30451-4

Ref. 378. Kim KH, et al. (2015) Nat Med, 21: 1491. Available from: https://doi.org/10.1038/nm.3968

Ref. 379. O’Haire S, et al. (2023) Scientific Reports, 13: 4116. Available from: https://doi.org/10.1038/s41598-023-31055-3

Ref. 380. Zhao X, et al. (2021) JCO Precis Oncol, 1. Available from: https://doi.org/10.1200/PO.20.00250

Ref. 381. US Food and Drug Administration. FDA Briefing Document. Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC). Accessed: August 31, 2025. Available from: https://www.fda.gov/media/178681/download

Ref. 382. Laetsch TW, et al. (2025) J Clin Oncol, 43: 1188. Available from: https://doi.org/10.1200/jco-24-01854

Ref. 383. Desai AV, et al. (2025) Eur J Cancer, 220: 115308. Available from: https://doi.org/10.1016/j.ejca.2025.115308

Ref. 384. Hong DS, et al. (2025) ESMO Open, 10: 105110. Available from: https://doi.org/10.1016/j.esmoop.2025.105110

Ref. 385. Duke ES, et al. (2023) Clin Cancer Res, 29: 3573. Available from: https://doi.org/10.1158/1078-0432.CCR-23-0459

Ref. 386. Ortiz MV, et al. (2020) JCO Precis Oncol, 4: 341. Available from: https://doi.org/10.1200/po.19.00401

Ref. 387. American Association for Cancer Research. AACR Cancer Progress Report 2023. Accessed: Feb 29, 2024. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2023/10/AACR_CPR_2023_102423.pdf

Ref. 388. Hiam-Galvez KJ, et al. (2021) Nat Rev Cancer, 21: 345. Available from: https://doi.org/10.1038/s41568-021-00347-z

Ref. 389. Mishra AK, et al. (2022) Diseases, 10: 60. Available from: https://doi.org/10.3390/diseases10030060

Ref. 390. Kaufmann SHE (2019) Front Immunol, 10: 684. Available from: https://doi.org/10.3389/fimmu.2019.00684

Ref. 391. Rohaan MW, et al. (2019) Virchows Arch, 474: 449. Available from: https://doi.org/10.1007/s00428-018-2484-0

Ref. 392. Maude SL, et al. (2018) N Engl J Med, 378: 439. Available from: https://doi.org/10.1056/NEJMoa1709866

Ref. 393. Laetsch TW, et al. (2023) Journal of Clinical Oncology, 41: 1664. Available from: https://doi.org/10.1200/Jco.22.00642

Ref. 394. US Food and Drug Administration. FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. Accessed: August 31, 2025. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor

Ref. 395. Mulvey A, et al. (2025) Nat Rev Drug Discov, 24: 379. Available from: https://doi.org/10.1038/s41573-024-01100-5

Ref. 396. Marin-Acevedo JA, et al. (2021) J Hematol Oncol, 14: 45. Available from: https://doi.org/10.1186/s13045-021-01056-8

Ref. 397. Long AH, et al. (2022) Am Soc Clin Oncol Educ Book, 42: 1. Available from: https://doi.org/10.1200/edbk_349799

Ref. 398. Das A, et al. (2023) Clin Cancer Res, 29: 4770. Available from: https://doi.org/10.1158/1078-0432.CCR-23-0411

Ref. 399. Negm L, et al. (2025) Lancet Oncol, 26: 123. Available from: https://doi.org/10.1016/s1470-2045(24)00640-5

Ref. 400. Chen AP, et al. (2023) N Engl J Med, 389: 911. Available from: https://doi.org/10.1056/NEJMoa2303383

Ref. 401. Yu AL, et al. (2021) Clin Cancer Res, 27: 2179. Available from: https://doi.org/10.1158/1078-0432.Ccr-20-3909

Ref. 402. Desai AV, et al. (2022) Journal of Clinical Oncology, 40: 4107. Available from: https://doi.org/10.1200/Jco.21.02478

Ref. 403. Minard-Colin V, et al. (2020) N Engl J Med, 382: 2207. Available from: https://doi.org/10.1056/NEJMoa1915315

Ref. 404. Brown PA, et al. (2021) JAMA, 325: 833. Available from: https://doi.org/10.1001/jama.2021.0669

Ref. 405. Locatelli F, et al. (2021) JAMA, 325: 843. Available from: https://doi.org/10.1001/jama.2021.0987

Ref. 406. Kantarjian H, et al. (2017) N Engl J Med, 376: 836. Available from: https://doi.org/10.1056/NEJMoa1609783

Ref. 407. Litzow MR, et al. (2024) N Engl J Med, 391: 320. Available from: https://doi.org/10.1056/NEJMoa2312948

Ref. 408. van der Sluis IM, et al. (2023) N Engl J Med, 388: 1572. Available from: https://doi.org/10.1056/NEJMoa2214171

Ref. 409. Gupta S, et al. (2025) N Engl J Med, 392: 875. Available from: https://doi.org/10.1056/NEJMoa2411680

Ref. 410. Laetsch TW, et al. (2021) Cancer Discov, 11: 545. Available from: https://doi.org/10.1158/2159-8290.Cd-20-0779

Ref. 411. Liu ITT, et al. (2024) Jama, 332: 1482. Available from: https://doi.org/10.1001/jama.2024.18338

Ref. 412. La Rosa S, et al. (2020) EMBO Mol Med, 12: e11656. Available from: https://doi.org/10.15252/emmm.201911656

Ref. 413. de Rojas T, et al. (2024) Clin Pharmacol Ther, 115: 36. Available from: https://doi.org/10.1002/cpt.3088

Ref. 414. Solis RN, et al. (2025) Endocrinology and Metabolism Clinics of North America, 54: 261. Available from: https://doi.org/10.1016/j.ecl.2025.02.001

Ref. 415. Kumar N, et al. (2025) Neurosurg Rev, 48: 334. Available from: https://doi.org/10.1007/s10143-025-03477-2

Ref. 416. Shoag J, et al. (2024) Pediatr Blood Cancer, 71: e31192. Available from: https://doi.org/10.1002/pbc.31192

Ref. 417. Liu X, et al. (2023) JAMA Netw Open, 6: e2251524. Available from: https://doi.org/10.1001/jamanetworkopen.2022.51524

Ref. 418. Thiesen A, et al. (2025) medRxiv. Available from: https://doi.org/10.1101/2025.06.10.25328700

Ref. 419. George SL, et al. (2025) Cancer Discovery, 15: 717. Available from: https://doi.org/10.1158/2159-8290.Cd-24-0916

Ref. 420. Liu ITT, et al. (2024) Pediatrics, 154. Available from: https://doi.org/10.1542/peds.2024-066920

Ref. 421. Lin S, et al. (2022) Cancer Discov, 12: 432. Available from: https://doi.org/10.1158/2159-8290.Cd-20-1851

Ref. 422. Mabe NW, et al. (2024) Nat Cancer, 5: 844. Available from: https://doi.org/10.1038/s43018-024-00777-2

Ref. 423. Mittal P, et al. (2020) Nat Rev Clin Oncol, 17: 435. Available from: https://doi.org/10.1038/s41571-020-0357-3

Ref. 424. Carter DR, et al. (2015) Sci Transl Med, 7: 312ra176. Available from: https://doi.org/10.1126/scitranslmed.aab1803

Ref. 425. Xiao L, et al. (2021) Clin Cancer Res, 27: 4338. Available from: https://doi.org/10.1158/1078-0432.Ccr-20-2357

Ref. 426. Ziegler DS, et al. (2025) Journal of Clinical Oncology, 43: 10051. Available from: https://doi.org/10.1200/JCO.2025.43.16_suppl.10051

Ref. 427. Singh S, et al. (2022) Sci Transl Med, 14: eabq2096. Available from: https://doi.org/10.1126/scitranslmed.abq2096

Ref. 428. Michmerhuizen NL, et al. (2025) Cancer Discovery: OF1. Available from: https://doi.org/10.1158/2159-8290.Cd-24-1772

Ref. 429. Seong BKA, et al. (2021) Cancer Cell, 39: 1262. Available from: https://doi.org/10.1016/j.ccell.2021.07.003

Ref. 430. Godfrey LC, et al. (2025) EMBO Rep. Available from: https://doi.org/10.1038/s44319-025-00552-z

Ref. 431. Wei E, et al. (2024) Molecular Cancer, 23: 222. Available from: https://doi.org/10.1186/s12943-024-02115-7

Ref. 432. Harlow ML, et al. (2019) Clin Cancer Res, 25: 3417. Available from: https://doi.org/10.1158/1078-0432.CCR-18-3511

Ref. 433. Weiss AR, et al. (2020) Lancet Oncol, 21: 1110. Available from: https://doi.org/10.1016/s1470-2045(20)30325-9

Ref. 434. Ridler C (2017) Nature Reviews Neurology, 13: 196. Available from: https://doi.org/10.1038/nrneurol.2017.39

Ref. 435. Garber K (2025) Nature, 641: 300. Available from: https://doi.org/10.1038/d41586-025-01350-2

Ref. 436. Tang J, et al. (2025) Cell Chem Biol, 32: 352. Available from: https://doi.org/10.1016/j.chembiol.2024.12.006

Ref. 437. Hu J, et al. (2022) Sci Transl Med, 14: eabo5228. Available from: https://doi.org/10.1126/scitranslmed.abo5228

Ref. 438. Cancer Grand Challenges. KOODAC. Accessed: August 31, 2025. Available from: https://www.cancergrandchallenges.org/koodac

Ref. 439. Cancer Grand Challenges. PROTECT. Accessed: August 31, 2025. Available from: https://www.cancergrandchallenges.org/protect

Ref. 440. Nguyen F, et al. (2020) Cancer Res, 80: 4258. Available from: https://doi.org/10.1158/0008-5472.Can-20-1344

Ref. 441. Hucks G, et al. (2019) Blood Cancer J, 9: 10. Available from: https://doi.org/10.1038/s41408-018-0164-6

Ref. 442. Shalabi H, et al. (2022) Blood, 140: 451. Available from: https://doi.org/10.1182/blood.2022015795

Ref. 443. Myers RM, et al. (2025) J Immunother Cancer, 13. Available from: https://doi.org/10.1136/jitc-2025-011549

Ref. 444. de Oliveira Canedo G, et al. (2025) Blood Adv, 9: 704. Available from: https://doi.org/10.1182/bloodadvances.2024013586

Ref. 445. Pan J, et al. (2025) Blood. Available from: https://doi.org/10.1182/blood.2025029299

Ref. 446. Pan J, et al. (2025) Nat Med, 31: 126. Available from: https://doi.org/10.1038/s41591-024-03282-2

Ref. 447. Zhao L, et al. (2025) Molecular Therapy, 33: 2753. Available from: https://doi.org/10.1016/j.ymthe.2024.09.006

Ref. 448. Naik S, et al. (2024) Haematologica, 109: 1656. Available from: https://doi.org/10.3324/haematol.2023.283817

Ref. 449. Zhang H, et al. (2022) Leukemia, 36: 2596. Available from: https://doi.org/10.1038/s41375-022-01703-0

Ref. 450. Zhang H, et al. (2021) Clin Cancer Res, 27: 3549. Available from: https://doi.org/10.1158/1078-0432.CCR-20-4543

Ref. 451. Pei K, et al. (2023) Cancer Med, 12: 9655. Available from: https://doi.org/10.1002/cam4.5916

Ref. 452. Timpanaro A, et al. (2025) Cancer Discovery, 15: 890. Available from: https://doi.org/10.1158/2159-8290.Cd-24-1465

Ref. 453. Lin FY, et al. (2024) J Clin Oncol, 42: 2769. Available from: https://doi.org/10.1200/JCO.23.02019

Ref. 454. Locatelli F, et al. (2025) Nat Med. Available from: https://doi.org/10.1038/s41591-025-03874-6

Ref. 455. Quintarelli C, et al. (2025) Nat Med, 31: 849. Available from: https://doi.org/10.1038/s41591-024-03449-x

Ref. 456. Wang K, et al. (2020) Nat Cancer, 1: 990. Available from: https://doi.org/10.1038/s43018-020-00119-y

Ref. 457. Mollica MA, et al. (2025) Cancer, 131: e70039. Available from: https://doi.org/10.1002/cncr.70039

Ref. 458. National Cancer Institute. Division of Cancer Control and Population Sciences. Statistics and Graphs. Accessed: August 31, 2025. Available from: https://cancercontrol.cancer.gov/ocs/statistics#definitions

Ref. 459. Ehrhardt MJ, et al. (2023) Nat Rev Clin Oncol, 20: 678. Available from: https://doi.org/10.1038/s41571-023-00802-w

Ref. 460. Wagle NS, et al. (2025) CA Cancer J Clin. Available from: https://doi.org/10.3322/caac.70011

Ref. 461. Mostoufi-Moab S, et al. (2016) J Clin Oncol, 34: 3240. Available from: https://doi.org/10.1200/JCO.2016.66.6545

Ref. 462. Rose SR, et al. (2016) Nat Rev Endocrinol, 12: 319. Available from: https://doi.org/10.1038/nrendo.2016.45

Ref. 463. Chemaitilly W, et al. (2017) Eur J Endocrinol, 176: R183. Available from: https://doi.org/10.1530/EJE-17-0054

Ref. 464. Chemaitilly W, et al. (2018) J Clin Oncol, 36: 2153. Available from: https://doi.org/10.1200/JCO.2017.76.3268

Ref. 465. Dixon SB, et al. (2023) Lancet, 401: 1447. Available from: https://doi.org/10.1016/S0140-6736(22)02471-0

Ref. 466. Bhandari R, et al. (2025) J Clin Oncol: JCO2500385. Available from: https://doi.org/10.1200/JCO-25-00385

Ref. 467. Ehrhardt MJ, et al. (2023) Lancet Oncol, 24: e108. Available from: https://doi.org/10.1016/S1470-2045(23)00012-8

Ref. 468. Mulrooney DA, et al. (2016) Ann Intern Med, 164: 93. Available from: https://doi.org/10.7326/M15-0424

Ref. 469. Haddy N, et al. (2016) Circulation, 133: 31. Available from: https://doi.org/10.1161/CIRCULATIONAHA.115.016686

Ref. 470. Bates JE, et al. (2019) J Clin Oncol, 37: 1090. Available from: https://doi.org/10.1200/JCO.18.01764

Ref. 471. Suh E, et al. (2020) Lancet Oncol, 21: 421. Available from: https://doi.org/10.1016/S1470-2045(19)30800-9

Ref. 472. Turcotte LM, et al. (2019) J Clin Oncol, 37: 3310. Available from: https://doi.org/10.1200/JCO.19.00129

Ref. 473. Turcotte LM, et al. (2015) J Clin Oncol, 33: 3568. Available from: https://doi.org/10.1200/JCO.2015.60.9487

Ref. 474. Teepen JC, et al. (2017) J Clin Oncol, 35: 2288. Available from: https://doi.org/10.1200/JCO.2016.71.6902

Ref. 475. Wang Z, et al. (2018) J Clin Oncol, 36: 2078. Available from: https://doi.org/10.1200/JCO.2018.77.8589

Ref. 476. Roganovic J (2025) World J Clin Cases, 13: 98000. Available from: https://doi.org/10.12998/wjcc.v13.i7.98000

Ref. 477. Turcotte LM, et al. (2018) J Clin Oncol, 36: 2145. Available from: https://doi.org/10.1200/JCO.2017.76.7764

Ref. 478. Ghosh T, et al. (2024) Cancer Med, 13: e70086. Available from: https://doi.org/10.1002/cam4.70086

Ref. 479. Chow EJ, et al. (2016) Lancet Oncol, 17: 567. Available from: https://doi.org/10.1016/S1470-2045(16)00086-3

Ref. 480. van Dorp W, et al. (2018) J Clin Oncol, 36: 2169. Available from: https://doi.org/10.1200/JCO.2017.76.3441

Ref. 481. Su HI, et al. (2025) J Clin Oncol, 43: 1488. Available from: https://doi.org/10.1200/JCO-24-02782

Ref. 482. van Dijk M, et al. (2020) J Cancer Res Clin Oncol, 146: 1451. Available from: https://doi.org/10.1007/s00432-020-03193-y

Ref. 483. Zgardau A, et al. (2022) J Natl Cancer Inst, 114: 553. Available from: https://doi.org/10.1093/jnci/djac005

Ref. 484. Yang EH, et al. (2024) Cancer, 130: 344. Available from: https://doi.org/10.1002/cncr.35108

Ref. 485. Gerstl B, et al. (2024) J Cancer Surviv, 18: 1201. Available from: https://doi.org/10.1007/s11764-023-01349-6

Ref. 486. Corona LE, et al. (2025) J Pediatr Surg, 60: 162400. Available from: https://doi.org/10.1016/j.jpedsurg.2025.162400

Ref. 487. Alliance for Fertility Preservation. State Laws & Legislation. Accessed: July 31, 2023. Available from: https://www.allianceforfertilitypreservation.org/expenses/laws-legislation/

Ref. 488. Phillips NS, et al. (2021) J Clin Oncol, 39: 1752. Available from: https://doi.org/10.1200/JCO.20.02533

Ref. 489. Jacola LM, et al. (2021) J Clin Oncol, 39: 1696. Available from: https://doi.org/10.1200/JCO.20.02444

Ref. 490. Gummersall T, et al. (2020) Crit Rev Oncol Hematol, 145: 102838. Available from: https://doi.org/10.1016/j.critrevonc.2019.102838

Ref. 491. Jacola LM, et al. (2016) Lancet Psychiatry, 3: 965. Available from: https://doi.org/10.1016/S2215-0366(16)30283-8

Ref. 492. Zheng DJ, et al. (2018) Cancer, 124: 3220. Available from: https://doi.org/10.1002/cncr.31379

Ref. 493. Prasad PK, et al. (2015) J Clin Oncol, 33: 2545. Available from: https://doi.org/10.1200/JCO.2014.57.7528

Ref. 494. Papini C, et al. (2025) Neuro Oncol, 27: 254. Available from: https://doi.org/10.1093/neuonc/noae119

Ref. 495. Phillips NS, et al. (2023) JAMA Netw Open, 6: e2316077. Available from: https://doi.org/10.1001/jamanetworkopen.2023.16077

Ref. 496. Barlow-Krelina E, et al. (2020) J Clin Oncol, 38: 2041. Available from: https://doi.org/10.1200/JCO.19.02677

Ref. 497. Guida JL, et al. (2024) Nat Cancer, 5: 731. Available from: https://doi.org/10.1038/s43018-024-00745-w

Ref. 498. Williams AM, et al. (2023) J Natl Cancer Inst, 115: 200. Available from: https://doi.org/10.1093/jnci/djac209

Ref. 499. Bhatia R, et al. (2022) Curr Oncol Rep, 24: 1401. Available from: https://doi.org/10.1007/s11912-022-01311-2

Ref. 500. Esbenshade AJ, et al. (2023) J Clin Oncol, 41: 3629. Available from: https://doi.org/10.1200/JCO.22.02240

Ref. 501. Wang Z, et al. (2025) Nat Rev Cancer, 25: 129. Available from: https://doi.org/10.1038/s41568-024-00768-6

Ref. 502. Ness KK, et al. (2018) J Clin Oncol, 36: 2206. Available from: https://doi.org/10.1200/JCO.2017.76.7467

Ref. 503. Wang S, et al. (2021) Cancers (Basel), 13. Available from: https://doi.org/10.3390/cancers13030427

Ref. 504. Dixon SB, et al. (2020) Pediatr Clin North Am, 67: 1237. Available from: https://doi.org/10.1016/j.pcl.2020.07.013

Ref. 505. Samis J, et al. (2016) Pediatr Blood Cancer, 63: 1332. Available from: https://doi.org/10.1002/pbc.26028

Ref. 506. Hijiya N, et al. (2021) Blood Adv, 5: 2925. Available from: https://doi.org/10.1182/bloodadvances.2020003759

Ref. 507. Millot F, et al. (2014) Eur J Cancer, 50: 3206. Available from: https://doi.org/10.1016/j.ejca.2014.10.007

Ref. 508. Versmissen J, et al. (2019) Cardiovasc Res, 115: 904. Available from: https://doi.org/10.1093/cvr/cvz022

Ref. 509. Chow EJ, et al. (2018) J Clin Oncol, 36: 2231. Available from: https://doi.org/10.1200/JCO.2017.76.4647

Ref. 510. Labrosse R, et al. (2021) J Allergy Clin Immunol, 148: 523. Available from: https://doi.org/10.1016/j.jaci.2021.03.041

Ref. 511. Brinkman TM, et al. (2016) J Clin Oncol, 34: 3417. Available from: https://doi.org/10.1200/JCO.2016.66.4789

Ref. 512. Marchak JG, et al. (2022) Lancet Oncol, 23: e184. Available from: https://doi.org/10.1016/S1470-2045(21)00750-6

Ref. 513. Brinkman TM, et al. (2018) J Clin Oncol, 36: 2190. Available from: https://doi.org/10.1200/JCO.2017.76.5552

Ref. 514. Hsu TW, et al. (2023) J Clin Oncol, 41: 2054. Available from: https://doi.org/10.1200/JCO.22.01189

Ref. 515. Pizzo A, et al. (2024) JAMA Netw Open, 7: e2436144. Available from: https://doi.org/10.1001/jamanetworkopen.2024.36144

Ref. 516. Tan JY, et al. (2025) JAMA Netw Open, 8: e2457544. Available from: https://doi.org/10.1001/jamanetworkopen.2024.57544

Ref. 517. Papini C, et al. (2023) Cancer, 129: 1117. Available from: https://doi.org/10.1002/cncr.34633

Ref. 518. Schulte F, et al. (2018) Cancer, 124: 3596. Available from: https://doi.org/10.1002/cncr.31593

Ref. 519. Somekh MR, et al. (2024) J Natl Cancer Inst, 116: 1952. Available from: https://doi.org/10.1093/jnci/djae194

Ref. 520. Vuotto SC, et al. (2024) Ann Clin Transl Neurol, 11: 291. Available from: https://doi.org/10.1002/acn3.51951

Ref. 521. Children’s Oncology Group. Long-Term Follow-up Guidelines for Survivors of Childhood, and Young Adult Cancers. Accessed: August 31, 2025. Available from: https://www.survivorshipguidelines.org/pdf/2025/COG_LTFU_Guidelines_Comprehensive_v6.pdf

Ref. 522. Code of Federal Regulations. Part 104—Nondiscrimination on the Basis of Handicap in Programs or Activities Receiving Federal Financial Assistance. Accessed: August 31, 2025. Available from: https://www.ecfr.gov/current/title-34/subtitle-B/chapter-I/part-104

Ref. 523. Code of Federal Regulations. Part 35—Nondiscrimination on the Basis of Disability in State and Local Government Services. Accessed: August 31, 2025. Available from: https://www.ecfr.gov/current/title-28/part-35

Ref. 524. Code of Federal Regulations. PART 300—Assistance to States for the Eeducation of Children with Disabilities. Accessed: August 31, 2025. Available from: https://www.ecfr.gov/current/title-34/subtitle-B/chapter-III/part-300

Ref. 525. Nipp RD, et al. (2017) J Clin Oncol, 35: 3474. Available from: https://doi.org/10.1200/JCO.2016.71.7066

Ref. 526. Nathan PC, et al. (2023) J Clin Oncol, 41: 1000. Available from: https://doi.org/10.1200/JCO.22.00572

Ref. 527. Huang IC, et al. (2019) J Natl Cancer Inst, 111: 189. Available from: https://doi.org/10.1093/jnci/djy120

Ref. 528. Bhatt NS, et al. (2024) JAMA Netw Open, 7: e2410731. Available from: https://doi.org/10.1001/jamanetworkopen.2024.10731

Ref. 529. Saatci D, et al. (2020) Arch Dis Child, 105: 339. Available from: https://doi.org/10.1136/archdischild-2019-317594

Ref. 530. Guy GP, Jr., et al. (2016) Pediatrics, 138: S15. Available from: https://doi.org/10.1542/peds.2015-4268D

Ref. 531. Kirchhoff AC, et al. (2024) J Natl Cancer Inst, 116: 1466. Available from: https://doi.org/10.1093/jnci/djae111

Ref. 532. Ehrhardt MJ, et al. (2023) JAMA Netw Open, 6: e2255395. Available from: https://doi.org/10.1001/jamanetworkopen.2022.55395

Ref. 533. Noyd DH, et al. (2023) JACC CardioOncol, 5: 489. Available from: https://doi.org/10.1016/j.jaccao.2023.01.011

Ref. 534. Noyd DH, et al. (2025) J Adolesc Young Adult Oncol. Available from: https://doi.org/10.1089/jayao.2024.0151

Ref. 535. Emerson MA, et al. (2022) JAMA Netw Open, 5: e2219122. Available from: https://doi.org/10.1001/jamanetworkopen.2022.19122

Ref. 536. Benedict C, et al. (2021) Transl Behav Med, 11: 132. Available from: https://doi.org/10.1093/tbm/ibz182

Ref. 537. Cousineau MR, et al. (2019) Inquiry, 56: 46958018817996. Available from: https://doi.org/10.1177/0046958018817996

Ref. 538. Gibson TM, et al. (2018) Lancet Oncol, 19: 1590. Available from: https://doi.org/10.1016/S1470-2045(18)30537-0

Ref. 539. Dixon SB, et al. (2020) J Clin Oncol, 38: 3418. Available from: https://doi.org/10.1200/JCO.20.00493

Ref. 540. Bhatia S, et al. (2021) Clin Cancer Res, 27: 967. Available from: https://doi.org/10.1158/1078-0432.CCR-20-3609

Ref. 541. Mulrooney DA, et al. (2009) BMJ, 339: b4606. Available from: https://doi.org/10.1136/bmj.b4606

Ref. 542. Chow EJ, et al. (2023) J Clin Oncol, 41: 2248. Available from: https://doi.org/10.1200/JCO.22.02423

Ref. 543. Asselin BL, et al. (2016) J Clin Oncol, 34: 854. Available from: https://doi.org/10.1200/JCO.2015.60.8851

Ref. 544. Meijer AJM, et al. (2022) Cancer, 128: 169. Available from: https://doi.org/10.1002/cncr.33848

Ref. 545. Brock PR, et al. (2018) N Engl J Med, 378: 2376. Available from: https://doi.org/10.1056/NEJMoa1801109

Ref. 546. Ohlsen TJD, et al. (2025) Pediatr Blood Cancer, 72: e31479. Available from: https://doi.org/10.1002/pbc.31479

Ref. 547. Ma J, et al. (2025) Pediatr Blood Cancer, 72: e31631. Available from: https://doi.org/10.1002/pbc.31631

Ref. 548. Zhou L, et al. (2025) J Clin Oncol: JCO2500542. Available from: https://doi.org/10.1200/JCO-25-00542

Ref. 549. Kim J, et al. (2021) JNCI Cancer Spectr, 5. Available from: https://doi.org/10.1093/jncics/pkab007

Ref. 550. Qin N, et al. (2020) J Clin Oncol, 38: 2728. Available from: https://doi.org/10.1200/JCO.19.02760

Ref. 551. Morton LM, et al. (2020) JCO Precis Oncol, 4. Available from: https://doi.org/10.1200/PO.20.00141

Ref. 552. Morton LM, et al. (2017) J Natl Cancer Inst, 109. Available from: https://doi.org/10.1093/jnci/djx058

Ref. 553. Sapkota Y, et al. (2019) J Invest Dermatol, 139: 2042. Available from: https://doi.org/10.1016/j.jid.2019.02.029

Ref. 554. Wang X, et al. (2023) J Clin Oncol, 41: 1758. Available from: https://doi.org/10.1200/JCO.22.01527

Ref. 555. Wang X, et al. (2016) J Clin Oncol, 34: 863. Available from: https://doi.org/10.1200/JCO.2015.63.4550

Ref. 556. Singh P, et al. (2020) Cancer, 126: 4051. Available from: https://doi.org/10.1002/cncr.32948

Ref. 557. Landier W, et al. (2004) J Clin Oncol, 22: 4979. Available from: https://doi.org/10.1200/JCO.2004.11.032

Ref. 558. DeVine A, et al. (2025) JAMA Oncol, 11: 544. Available from: https://doi.org/10.1001/jamaoncol.2024.6812

Ref. 559. Hudson MM, et al. (2021) Pediatrics, 148. Available from: https://doi.org/10.1542/peds.2021-053127

Ref. 560. Effinger KE, et al. (2023) J Cancer Surviv, 17: 1139. Available from: https://doi.org/10.1007/s11764-021-01157-w

Ref. 561. Ford JS, et al. (2020) Cancer, 126: 619. Available from: https://doi.org/10.1002/cncr.32568

Ref. 562. Milam J, et al. (2024) Pediatr Blood Cancer, 71: e31328. Available from: https://doi.org/10.1002/pbc.31328

Ref. 563. Marchak JG, et al. (2023) J Cancer Surviv, 17: 342. Available from: https://doi.org/10.1007/s11764-023-01351-y

Ref. 564. Sadak KT, et al. (2019) Pediatr Blood Cancer, 66: e27793. Available from: https://doi.org/10.1002/pbc.27793

Ref. 565. Jacobs LA, et al. (2017) Lancet Oncol, 18: e19. Available from: https://doi.org/10.1016/S1470-2045(16)30386-2

Ref. 566. Gilbert R, et al. (2025) Clinical Practice in Pediatric Psychology, 13: 180. Available from: https://doi.org/10.1177/21694826251319301

Ref. 567. Wadhwa A, et al. (2019) Cancer, 125: 3864. Available from: https://doi.org/10.1002/cncr.32391

Ref. 568. Nekhlyudov L, et al. (2017) Lancet Oncol, 18: e30. Available from: https://doi.org/10.1016/S1470-2045(16)30570-8

Ref. 569. Bradford N, et al. (2024) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-024-01610-6

Ref. 570. Yan AP, et al. (2020) J Clin Oncol, 38: 1711. Available from: https://doi.org/10.1200/JCO.19.01825

Ref. 571. Iyer NS, et al. (2017) Support Care Cancer, 25: 1547. Available from: https://doi.org/10.1007/s00520-016-3544-0

Ref. 572. Children’s Oncology Group. Passport for Care. Accessed: August 31, 2025. Available from: https://cancersurvivor.passportforcare.org/en/

Ref. 573. King JE, et al. (2023) Pediatr Blood Cancer, 70: e30070. Available from: https://doi.org/10.1002/pbc.30070

Ref. 574. Leahy AB, et al. (2020) JAMA Pediatr, 174: e202868. Available from: https://doi.org/10.1001/jamapediatrics.2020.2868

Ref. 575. Yan AP, et al. (2025) EJC Paediatric Oncology, 5. Available from: https://doi.org/10.1016/j.ejcped.2025.100238

Ref. 576. Reeve BB, et al. (2023) Am Soc Clin Oncol Educ Book, 43: e390272. Available from: https://doi.org/10.1200/EDBK_390272

Ref. 577. Perry MB, et al. (2024) J Med Internet Res, 26: e49089. Available from: https://doi.org/10.2196/49089

Ref. 578. Tomlinson D, et al. (2019) BMC Cancer, 19: 32. Available from: https://doi.org/10.1186/s12885-018-5210-z

Ref. 579. Horan MR, et al. (2022) Children (Basel), 9. Available from: https://doi.org/10.3390/children9101497

Ref. 580. Tomlinson D, et al. (2023) BMJ Support Palliat Care, 13: e469. Available from: https://doi.org/10.1136/bmjspcare-2021-003169

Ref. 581. Dupuis LL, et al. (2025) JAMA Pediatr, 179: 11. Available from: https://doi.org/10.1001/jamapediatrics.2024.4727

Ref. 582. Dupuis LL, et al. (2024) JAMA, 332: 1981. Available from: https://doi.org/10.1001/jama.2024.19585

Ref. 583. Rusconi D, et al. (2024) J Palliat Care, 39: 298. Available from: https://doi.org/10.1177/08258597241274027

Ref. 584. Merz A, et al. (2023) J Pain Symptom Manage, 66: e327. Available from: https://doi.org/10.1016/j.jpainsymman.2023.05.016

Ref. 585. Murugappan MN, et al. (2022) J Natl Cancer Inst, 114: 12. Available from: https://doi.org/10.1093/jnci/djab087

Ref. 586. Rothmund M, et al. (2022) Crit Rev Oncol Hematol, 176: 103755. Available from: https://doi.org/10.1016/j.critrevonc.2022.103755

Ref. 587. Colbert JA, et al. (2025) JAMA Oncol, 11: 233. Available from: https://doi.org/10.1001/jamaoncol.2024.6157

Ref. 588. Zhao B, et al. (2025) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-025-01788-3

Ref. 589. Wong CL, et al. (2024) BMJ Open, 14: e087343. Available from: https://doi.org/10.1136/bmjopen-2024-087343

Ref. 590. van Warmerdam J, et al. (2019) Pediatr Blood Cancer, 66: e27677. Available from: https://doi.org/10.1002/pbc.27677

Ref. 591. Hu X, et al. (2024) JAMA Netw Open, 7: e244531. Available from: https://doi.org/10.1001/jamanetworkopen.2024.4531

Ref. 592. Pierce L, et al. (2017) Psychooncology, 26: 1555. Available from: https://doi.org/10.1002/pon.4171

Ref. 593. Roser K, et al. (2019) Psychooncology, 28: 1207. Available from: https://doi.org/10.1002/pon.5088

Ref. 594. Santacroce SJ, et al. (2020) Pediatr Blood Cancer, 67: e28093. Available from: https://doi.org/10.1002/pbc.28093

Ref. 595. Evans EM, et al. (2023) Pediatr Blood Cancer: e30496. Available from: https://doi.org/10.1002/pbc.30496

Ref. 596. Lin JJ, et al. (2024) Pediatr Blood Cancer, 71: e30890. Available from: https://doi.org/10.1002/pbc.30890

Ref. 597. Wiener L, et al. (2015) Pediatr Blood Cancer, 62 Suppl 5: S419. Available from: https://doi.org/10.1002/pbc.25675

Ref. 598. Scialla MA, et al. (2017) Pediatr Blood Cancer, 64. Available from: https://doi.org/10.1002/pbc.26634

Ref. 599. Scialla MA, et al. (2018) Pediatr Blood Cancer, 65. Available from: https://doi.org/10.1002/pbc.26869

Ref. 600. Scialla MA, et al. (2025) Pediatr Blood Cancer, 72: e31676. Available from: https://doi.org/10.1002/pbc.31676

Ref. 601. Wiener L, et al. (2020) Pediatr Blood Cancer, 67: e28586. Available from: https://doi.org/10.1002/pbc.28586

Ref. 602. Bhakta N, et al. (2019) Lancet Oncol, 20: e42. Available from: https://doi.org/10.1016/s1470-2045(18)30761-7

Ref. 603. Noyd DH, et al. (2025) JCO Glob Oncol, 11: e2400274. Available from: https://doi.org/10.1200/GO-24-00274

Ref. 604. Ferlay J, et al. (2019) Int J Cancer, 144: 1941. Available from: https://doi.org/10.1002/ijc.31937

Ref. 605. Ward ZJ, et al. (2019) Lancet Oncol, 20: 483. Available from: https://doi.org/10.1016/S1470-2045(18)30909-4

Ref. 606. International Agency for Research on Cancer. Cancer Tomorrow. Accessed: August 31, 2025. Available from: https://gco.iarc.who.int/today/

Ref. 607. Wang M, et al. (2025) eClinicalMedicine, 89. Available from: https://doi.org/10.1016/j.eclinm.2025.103571

Ref. 608. Johnston WT, et al. (2021) Cancer Epidemiology, 71: 101662. Available from: https://doi.org/10.1016/j.canep.2019.101662

Ref. 609. The World Bank. World Bank Country and Lending Groups. Accessed: August 31, 2025. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups

Ref. 610. World Health Organization. CureAll framework: WHO Global Initiative for Childhood Cancer. Increasing Access, Advancing quality, Saving lives. Accessed: August 31, 2025. Available from: https://iris.who.int/bitstream/handle/10665/347370/9789240025271-eng.pdf?sequence=1

Ref. 611. Seneviwickrama M, et al. (2025) BMC Cancer, 25: 181. Available from: https://doi.org/10.1186/s12885-025-13586-2

Ref. 612. Chawla B, et al. (2017) Asia Pac J Oncol Nurs, 4: 187. Available from: https://doi.org/10.4103/apjon.apjon_19_17

Ref. 613. Wong ES, et al. (2022) Lancet Glob Health, 10: e380. Available from: https://doi.org/10.1016/s2214-109x(21)00555-6

Ref. 614. Joseph AO, et al. (2021) Journal of Clinical Sciences, 18.

Ref. 615. Winestone LE, et al. (2024) Pediatr Blood Cancer, 71: e30997. Available from: https://doi.org/10.1002/pbc.30997

Ref. 616. Nabukalu D, et al. (2024) Cancer Med, 13: e6925. Available from: https://doi.org/10.1002/cam4.6925

Ref. 617. Rahman SA, et al. (2023) Asian Pac J Cancer Prev, 24: 69. Available from: https://doi.org/10.31557/apjcp.2023.24.1.69

Ref. 618. Pretorius L, et al. (2025).

Ref. 619. Friedrich P, et al. (2016) PLoS One, 11: e0163090. Available from: https://doi.org/10.1371/journal.pone.0163090

Ref. 620. Dimaras H, et al. (2012) Lancet, 379: 1436. Available from: https://doi.org/10.1016/S0140-6736(11)61137-9

Ref. 621. Sitorus RS, et al. (2009) Ophthalmic Genet, 30: 31. Available from: https://doi.org/10.1080/13816810802464320

Ref. 622. Chantada GL, et al. (2011) Pediatr Blood Cancer, 56: 341. Available from: https://doi.org/10.1002/pbc.22843

Ref. 623. Olteanu C, et al. (2016) Ophthalmic Genet, 37: 137. Available from: https://doi.org/10.3109/13816810.2014.937543

Ref. 624. Counts LE, et al. (2025) JCO Glob Oncol, 11: e2400213. Available from: https://doi.org/10.1200/go.24.00213

Ref. 625. Ward ZJ, et al. (2019) Lancet Oncol, 20: 972. Available from: https://doi.org/10.1016/S1470-2045(19)30273-6

Ref. 626. Wu Y, et al. (2022) J Adv Res, 40: 233. Available from: https://doi.org/10.1016/j.jare.2022.06.001

Ref. 627. Ding F, et al. (2025) Front Pediatr, 13: 1542649. Available from: https://doi.org/10.3389/fped.2025.1542649

Ref. 628. Li T, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17050892

Ref. 629. Klootwijk L, et al. (2025) J Cancer Educ, 40: 54. Available from: https://doi.org/10.1007/s13187-024-02468-z

Ref. 630. Moormann AM, et al. (2016) Current Opinion in Virology, 20: 78. Available from: https://doi.org/10.1016/j.coviro.2016.09.006

Ref. 631. Njuguna F, et al. (2016) Pediatr Hematol Oncol, 33: 186. Available from: https://doi.org/10.3109/08880018.2016.1169566

Ref. 632. Handayani K, et al. (2016) Pediatr Blood Cancer, 63: 2189. Available from: https://doi.org/10.1002/pbc.26174

Ref. 633. Rugwizangoga B, et al. (2022) Cancer Manag Res, 14: 1923. Available from: https://doi.org/10.2147/cmar.S362882

Ref. 634. Ahmed MM, et al. (2025) Sage Open Pediatrics, 12: 30502225251336861. Available from: https://doi.org/10.1177/30502225251336861

Ref. 635. Afungchwi GM, et al. (2022) Pediatr Blood Cancer, 69: e29675. Available from: https://doi.org/10.1002/pbc.29675

Ref. 636. Afungchwi GM, et al. (2017) BMC Complement Altern Med, 17: 209. Available from: https://doi.org/10.1186/s12906-017-1719-y

Ref. 637. Lubega J, et al. (2021) Curr Opin Pediatr, 33: 33. Available from: https://doi.org/10.1097/MOP.0000000000000984

Ref. 638. Fabian ID, et al. (2020) JAMA Oncol, 6: 685. Available from: https://doi.org/10.1001/jamaoncol.2019.6716

Ref. 639. Williams LA, et al. (2021) Int J Epidemiol, 50: 116. Available from: https://doi.org/10.1093/ije/dyaa176

Ref. 640. Lu VM, et al. (2023) World Neurosurg, 179: e568. Available from: https://doi.org/10.1016/j.wneu.2023.09.003

Ref. 641. Huangfu B, et al. (2025) Scientific Reports, 15: 17049. Available from: https://doi.org/10.1038/s41598-025-01368-6

Ref. 642. Arnautovic A, et al. (2015) Childs Nerv Syst, 31: 1067. Available from: https://doi.org/10.1007/s00381-015-2670-1

Ref. 643. van Heerden J, et al. (2023) Pediatric Hematology and Oncology, 40: 203. Available from: https://doi.org/10.1080/08880018.2022.2140860

Ref. 644. Moreira DC, et al. (2023) JCO Glob Oncol, 9: e2300017. Available from: https://doi.org/10.1200/go.23.00017

Ref. 645. van Heerden J, et al. (2025) Frontiers in Cancer Control and Society, Volume 3 – 2025. Available from: https://doi.org/10.3389/fcacs.2025.1528695

Ref. 646. Espinoza P, et al. (2025) Lancet Oncol, 26: 421. Available from: https://doi.org/10.1016/S1470-2045(24)00559-X

Ref. 647. World Health Organization. WHO Global Initiative for Childhood Cancer on the path to bridging the Survival Gap and attaining Universal Health Coverage: a 5-Year

Ref. 648. Ortiz R, et al. (2023) Rev Panam Salud Publica, 47: e164. Available from: https://doi.org/10.26633/RPSP.2023.164

Ref. 649. Vasquez L, et al. (2023) Rev Panam Salud Publica, 47: e144. Available from: https://doi.org/10.26633/RPSP.2023.144

Ref. 650. Moreira DC, et al. (2024) JCO Glob Oncol, 10: e2300334. Available from: https://doi.org/10.1200/GO.23.00334

Ref. 651. International Society of Paediatric Oncology. About. Accessed: August 31, 2025. Available from: https://siop-online.org/about/

Ref. 652. ARIA Guide. Pediatric Oncology Guidelines. Accessed: August 31, 2025. Available from: https://aria.stjude.org/about

Ref. 653. World Health Organization. Research and development landscape for childhood cancer: a 2023 perspective. Accessed: August 31, 2025. Available from: https://iris.who.int/bitstream/handle/10665/373665/9789240082533-eng.pdf

Ref. 654. de Rojas T, et al. (2021) Cancer Med, 10: 8462. Available from: https://doi.org/10.1002/cam4.4356

Ref. 655. WIRB-Copernicus Group. The FDA Accepts ICH E11A on Pediatric Extrapolation: How Does This Impact Your Pediatric Study? Accessed: August 31, 2025. Available from: https://www.wcgclinical.com/insights/the-fda-accepts-ich-e11a-on-pediatric-extrapolation-how-does-this-impact-your-pediatric-study/

Ref. 656. Langenberg KPS, et al. (2022) Eur J Cancer, 175: 311. Available from: https://doi.org/10.1016/j.ejca.2022.09.001

Ref. 657. Lau LMS, et al. (2024) Nat Med, 30: 1913. Available from: https://doi.org/10.1038/s41591-024-03044-0

Ref. 658. Barlow-Stewart K, et al. (2025) NPJ Genom Med, 10: 12. Available from: https://doi.org/10.1038/s41525-025-00470-y

Ref. 659. Plana A, et al. (2021) JCO Clin Cancer Inform, 5: 1034. Available from: https://doi.org/10.1200/CCI.21.00075

Ref. 660. Boutros M, et al. (2024) Cancer Discov, 14: 30. Available from: https://doi.org/10.1158/2159-8290.CD-23-1111

Ref. 661. Farouk Sait S, et al. (2025) Clin Cancer Res, 31: 3285. Available from: https://doi.org/10.1158/1078-0432.CCR-24-3910

Ref. 662. Nishiwaki S, et al. (2020) Sci Rep, 10: 17145. Available from: https://doi.org/10.1038/s41598-020-73028-w

Ref. 663. Geoerger B, et al. (2023) Nat Med, 29: 2985. Available from: https://doi.org/10.1038/s41591-023-02580-5

Ref. 664. Major A, et al. (2022) JCO Glob Oncol, 8: e2100266. Available from: https://doi.org/10.1200/GO.21.00266

Ref. 665. Loucaides EM, et al. (2019) Lancet Oncol, 20: e672. Available from: https://doi.org/10.1016/S1470-2045(19)30662-X

Ref. 666. Li CK, et al. (2023) JCO Glob Oncol, 9: e2300153. Available from: https://doi.org/10.1200/GO.23.00153

Ref. 667. Arora RS, et al. (2021) Lancet Child Adolesc Health, 5: 239. Available from: https://doi.org/10.1016/S2352-4642(21)00056-0

Ref. 668. van Heerden J, et al. (2020) JCO Glob Oncol, 6: 1264. Available from: https://doi.org/10.1200/GO.20.00159

Ref. 669. Gupta S, et al. Treating Childhood Cancer in Low- and Middle-Income Countries. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC): The International Bank for Reconstruction and Development / The World Bank

Ref. 670. Ehrlich BS, et al. (2023) Lancet Oncol, 24: 967. Available from: https://doi.org/10.1016/S1470-2045(23)00318-2

Ref. 671. Diorio C, et al. (2017) J Glob Oncol, 3: 791. Available from: https://doi.org/10.1200/JGO.2016.005587

Ref. 672. Hudson MM, et al. (2014) J Clin Oncol, 32: 2391. Available from: https://doi.org/10.1200/JCO.2014.55.6571

Ref. 673. DelRocco NJ, et al. (2024) Leukemia, 38: 720. Available from: https://doi.org/10.1038/s41375-024-02166-1

Ref. 674. Pui CH, et al. (2006) N Engl J Med, 354: 166. Available from: https://doi.org/10.1056/NEJMra052603

Ref. 675. Kantarjian H, et al. (2025) Lancet, 406: 950. Available from: https://doi.org/10.1016/S0140-6736(25)00864-5

Ref. 676. Hayashi H, et al. (2024) Cancers (Basel), 16. Available from: https://doi.org/10.3390/cancers16040723

Ref. 677. Tran TH, et al. (2022) Semin Cancer Biol, 84: 144. Available from: https://doi.org/10.1016/j.semcancer.2020.10.013

Ref. 678. Pui CH, et al. (2019) Nat Rev Clin Oncol, 16: 227. Available from: https://doi.org/10.1038/s41571-018-0136-6

Ref. 679. Lejman M, et al. (2021) Int J Mol Sci, 22. Available from: https://doi.org/10.3390/ijms22189827

Ref. 680. Kim H, et al. (2025) Blood Res, 60: 40. Available from: https://doi.org/10.1007/s44313-025-00085-3

Ref. 681. Ray A, et al. (2024) Children (Basel), 11. Available from: https://doi.org/10.3390/children11111329

Ref. 682. Gogoi MP, et al. (2025) Lancet Reg Health Southeast Asia, 37: 100593. Available from: https://doi.org/10.1016/j.lansea.2025.100593

Ref. 683. Das N, et al. (2022) Trials, 23: 102. Available from: https://doi.org/10.1186/s13063-022-06033-1

Ref. 684. Duffy C, et al. (2023) Front Oncol, 13: 1254233. Available from: https://doi.org/10.3389/fonc.2023.1254233

Ref. 685. Cappellano A, et al. (2024) Pediatr Blood Cancer, 71: e30973. Available from: https://doi.org/10.1002/pbc.30973

Ref. 686. Duffy C, et al. (2024) Cancer, 130: 2247. Available from: https://doi.org/10.1002/cncr.35290

Ref. 687. Wang Y, et al. (2024) Cancer Res Treat, 56: 945. Available from: https://doi.org/10.4143/crt.2023.1205

Ref. 688. Narula G, et al. (2025) Blood Cancer J, 15: 75. Available from: https://doi.org/10.1038/s41408-025-01279-9

Ref. 689. Alfaro-Hernandez L, et al. (2025) Front Oncol, 15: 1614445. Available from: https://doi.org/10.3389/fonc.2025.1614445

Ref. 690. Ahmad I, et al. (2023) JCO Glob Oncol, 9: e2200288. Available from: https://doi.org/10.1200/GO.22.00288

Ref. 691. Molla YM, et al. (2025) Sci Rep, 15: 10534. Available from: https://doi.org/10.1038/s41598-025-90493-3

Ref. 692. Anacak Y, et al. (2021) Clin Oncol (R Coll Radiol), 33: e211. Available from: https://doi.org/10.1016/j.clon.2020.11.004

Ref. 693. Geel JA, et al. (2021) Pediatr Blood Cancer, 68: e29345. Available from: https://doi.org/10.1002/pbc.29345

Ref. 694. Wilfinger MJ, et al. (2025) Lancet Glob Health, 13: e1250. Available from: https://doi.org/10.1016/S2214-109X(25)00138-X

Ref. 695. Galvan-Barrios J, et al. (2025) Ann Med Surg (Lond), 87: 4676. Available from: https://doi.org/10.1097/MS9.0000000000003380

Ref. 696. Burki T (2025) Lancet Oncol, 26: e130. Available from: https://doi.org/10.1016/S1470-2045(25)00095-6

Ref. 697. Downing JR, et al. (2025) Lancet Oncol, 26: 540. Available from: https://doi.org/10.1016/S1470-2045(25)00146-9

Ref. 698. Adepoju P (2025) Lancet Oncol. Available from: https://doi.org/10.1016/S1470-2045(25)00550-9

Ref. 699. Nishath T, et al. (2023) Br J Ophthalmol, 107: 1818. Available from: https://doi.org/10.1136/bjo-2022-321159

Ref. 700. Adegoke S, et al. (2024) Health Sci Rep, 7: e70084. Available from: https://doi.org/10.1002/hsr2.70084

Ref. 701. Luna-Fineman S, et al. (2024) Pediatr Blood Cancer, 71: e30792. Available from: https://doi.org/10.1002/pbc.30792

Ref. 702. Langat S, et al. (2023) Support Care Cancer, 31: 467. Available from: https://doi.org/10.1007/s00520-023-07913-1

Ref. 703. Khofi H, et al. (2025) Pediatr Blood Cancer, 72: e32021. Available from: https://doi.org/10.1002/pbc.32021

Ref. 704. Holmes DM, et al. (2023) Pediatr Blood Cancer, 70: e30242. Available from: https://doi.org/10.1002/pbc.30242

Ref. 705. Nri-Ezedi CA, et al. (2024) BMC Cancer, 24: 943. Available from: https://doi.org/10.1186/s12885-024-12723-7

Ref. 706. Tan RJD, et al. (2024) Int J Ophthalmol, 17: 144. Available from: https://doi.org/10.18240/ijo.2024.01.20

Ref. 707. Chapman H, et al. (2024) Pediatr Blood Cancer, 71: e31145. Available from: https://doi.org/10.1002/pbc.31145

Ref. 708. Otsokolhich M, et al. (2024) EJC Paediatric Oncology, 3: 100163. Available from: https://doi.org/10.1016/j.ejcped.2024.100163

Ref. 709. Burki TK (2021) Lancet Haematol, 8: e252. Available from: https://doi.org/10.1016/S2352-3026(21)00068-5

Ref. 710. Martinez-Gamboa DA, et al. (2025) Crit Rev Oncol Hematol, 209: 104648. Available from: https://doi.org/10.1016/j.critrevonc.2025.104648

Ref. 711. Kim SJ, et al. (2024) Ann Lab Med, 44: 210. Available from: https://doi.org/10.3343/alm.2023.0388

Ref. 712. Bucklein V, et al. (2023) Hemasphere, 7: e907. Available from: https://doi.org/10.1097/HS9.0000000000000907

Ref. 713. Mallapaty S (2024) Nature, 627: 709. Available from: https://doi.org/10.1038/d41586-024-00809-y

Ref. 714. Reiterova M, et al. (2025) Clin Chem Lab Med, 63: 1419. Available from: https://doi.org/10.1515/cclm-2024-1503

Ref. 715. Radich JP, et al. (2022) Annu Rev Pathol, 17: 387. Available from: https://doi.org/10.1146/annurev-pathol-042320-034052

Ref. 716. Kaur K, et al. (2019) J Neurooncol, 143: 393. Available from: https://doi.org/10.1007/s11060-019-03187-y

Ref. 717. Rao S, et al. (2024) Brain Tumor Pathol, 41: 109. Available from: https://doi.org/10.1007/s10014-024-00487-8

Ref. 718. Jain R, et al. (2021) Pediatr Hematol Oncol, 38: 291. Available from: https://doi.org/10.1080/08880018.2020.1850955

Ref. 719. Shen AL, et al. (2023) Pediatr Blood Cancer, 70: e30680. Available from: https://doi.org/10.1002/pbc.30680

Ref. 720. Denburg AE, et al. (2022) JCO Glob Oncol, 8: e2200034. Available from: https://doi.org/10.1200/GO.22.00034

Ref. 721. Xie S, et al. (2024) Health Econ Rev, 14: 38. Available from: https://doi.org/10.1186/s13561-024-00514-6

Ref. 722. Sathyanarayanan V, et al. (2020) JCO Glob Oncol, 6: 1124. Available from: https://doi.org/10.1200/GO.20.00012

Ref. 723. Moreira DC, et al. (2024) CNS Drugs, 38: 841. Available from: https://doi.org/10.1007/s40263-024-01121-z

Ref. 724. ClinicalTrials.gov. Study Details | NCT06528691 | Entrectinib as a Single Agent in Upfront Therapy for Children. Accessed: October 17, 2025. Available from: https://clinicaltrials.gov/study/NCT06528691

Ref. 725. Aristizabal P, et al. (2021) Am Soc Clin Oncol Educ Book, 41: e315. Available from: https://doi.org/10.1200/EDBK_320499

Ref. 726. Mohan R (2022) Precis Radiat Oncol, 6: 164. Available from: https://doi.org/10.1002/pro6.1149

Ref. 727. Parkes J, et al. (2017) Pediatr Blood Cancer, 64 Suppl 5. Available from: https://doi.org/10.1002/pbc.26903

Ref. 728. International Atomic Energy Agency. Rays of Hope. Accessed: Oct 17, 2025. Available from: https://www.iaea.org/bulletin/rays-of-hope

Ref. 729. International Atomic Energy Agency. IAEA and St. Jude Children’s Research Hospital Partner to Bridge Gap in Global Childhood Cancer Care | International Atomic Energy Agency. Accessed: Oct 17, 2025. Available from: https://www.iaea.org/newscenter/pressreleases/iaea-and-st-jude-childrens-research-hospital-partner-to-bridge-gap-in-global-childhood-cancer-care

Ref. 730. Cui Y, et al. (2024) J Glob Health, 14: 04045. Available from: https://doi.org/10.7189/jogh.14.04045

Ref. 731. Li X, et al. (2025) Front Public Health, 13: 1513526. Available from: https://doi.org/10.3389/fpubh.2025.1513526

Ref. 732. Ribeiro RC, et al. (2016) J Clin Oncol, 34: 53. Available from: https://doi.org/10.1200/JCO.2015.61.9148

Ref. 733. Chitsike I, et al. (2020) JCO Glob Oncol, 6: 1076. Available from: https://doi.org/10.1200/GO.20.00170

Ref. 734. Lehrnbecher T, et al. (2023) J Clin Oncol, 41: 1774. Available from: https://doi.org/10.1200/JCO.22.02224

Ref. 735. Nellis ME, et al. (2019) Hematol Oncol Clin North Am, 33: 903. Available from: https://doi.org/10.1016/j.hoc.2019.05.011

Ref. 736. Kruimer DM, et al. (2024) Support Care Cancer, 32: 766. Available from: https://doi.org/10.1007/s00520-024-08888-3

Ref. 737. Walker R, et al. (2024) Support Care Cancer, 32: 747. Available from: https://doi.org/10.1007/s00520-024-08939-9

Ref. 738. Lo AC, et al. (2024) JAMA Netw Open, 7: e2351062. Available from: https://doi.org/10.1001/jamanetworkopen.2023.51062

Ref. 739. Martos M, et al. (2025) JAMA Oncol. Available from: https://doi.org/10.1001/jamaoncol.2025.2506

Ref. 740. Signorelli C, et al. (2024) JCO Glob Oncol, 10: e2300418. Available from: https://doi.org/10.1200/GO.23.00418

Ref. 741. Lemmen J, et al. (2023) Crit Rev Oncol Hematol, 185: 103981. Available from: https://doi.org/10.1016/j.critrevonc.2023.103981

Ref. 742. Vaishnav M, et al. (2023) Indian J Psychiatry, 65: 995. Available from: https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_667_23

Ref. 743. Sapag JC, et al. (2018) Glob Public Health, 13: 1468. Available from: https://doi.org/10.1080/17441692.2017.1356347

Ref. 744. Alemu WG, et al. (2023) BMC Psychiatry, 23: 480. Available from: https://doi.org/10.1186/s12888-023-04950-2

Ref. 745. Siddiqui MF, et al. (2023) Glob Pediatr Health, 10: 2333794X231188591. Available from: https://doi.org/10.1177/2333794X231188591

Ref. 746. Delgado E, et al. (2010) Eur J Cancer, 46: 2260. Available from: https://doi.org/10.1016/j.ejca.2010.05.006

Ref. 747. Downing J, et al. (2024) Ecancermedicalscience, 18: 1823. Available from: https://doi.org/10.3332/ecancer.2024.1823

Ref. 748. Salins N, et al. (2022) Curr Oncol Rep, 24: 175. Available from: https://doi.org/10.1007/s11912-021-01170-3

Ref. 749. Valery PC, et al. (2020) Lancet Oncol, 21: 489. Available from: https://doi.org/10.1016/S1470-2045(20)30137-6

Ref. 750. Makamo N, et al. (2025) BMJ Glob Health, 10. Available from: https://doi.org/10.1136/bmjgh-2025-019345

Ref. 751. Pineros M, et al. (2021) J Natl Cancer Inst, 113: 9. Available from: https://doi.org/10.1093/jnci/djaa069

Ref. 752. Janssens GO, et al. (2024) Radiother Oncol, 191: 110075. Available from: https://doi.org/10.1016/j.radonc.2023.110075

Ref. 753. Roach JT, et al. (2023) JCO Glob Oncol, 9: e2200402. Available from: https://doi.org/10.1200/GO.22.00402

Ref. 754. Hastings C, et al. (2023) Pediatr Blood Cancer, 70: e30221. Available from: https://doi.org/10.1002/pbc.30221

Ref. 755. Khan MS, et al. (2021) Pediatr Blood Cancer, 68: e29190. Available from: https://doi.org/10.1002/pbc.29190

Ref. 756. Fischer AN, et al. (2021) Pediatr Blood Cancer, 68: e28958. Available from: https://doi.org/10.1002/pbc.28958

Ref. 757. Sniderman ER, et al. (2022) Cancer, 128: 1493. Available from: https://doi.org/10.1002/cncr.34090

Ref. 758. Trapani D, et al. (2021) ESMO Open, 6: 100292. Available from: https://doi.org/10.1016/j.esmoop.2021.100292

Ref. 759. Fufa D, et al. (2025) BMJ Glob Health, 10. Available from: https://doi.org/10.1136/bmjgh-2024-017502

Ref. 760. Ni X, et al. (2022) Lancet, 400: 1020. Available from: https://doi.org/10.1016/S0140-6736(22)01541-0

Ref. 761. Robison LL, et al. (2009) J Clin Oncol, 27: 2308. Available from: https://doi.org/10.1200/jco.2009.22.3339

Ref. 762. National Cancer Institute. NCI Budget Fact Book. Accessed: August 31, 2025. Available from: https://www.cancer.gov/about-nci/budget/fact-book

Ref. 763. National Cancer Institute. An Analysis of the National Cancer Institute’s Investment in Pediatric Cancer Research. Accessed: August 31, 2025. Available from: https://www.cancer.gov/types/childhood-cancers/research/pediatric-analysis.pdf

Ref. 764. OncoDaily. Trump Signs Executive Order Doubling AI Funding for Pediatric Cancer Research. Accessed: October 8, 2025. Available from: https://oncodaily.com/positive/president-trump-pediatric-cancer-ai-2025

Ref. 765. The Future Pediatric Subspecialty Physician Workforce: Meeting the Needs of Infants, Children, and Adolescents. Washington (DC)2023.

Ref. 766. Winestone LE, et al. (2023) Pediatr Blood Cancer, 70 Suppl 6: e30592. Available from: https://doi.org/10.1002/pbc.30592

Ref. 767. Syrimi E, et al. (2020) JCO Glob Oncol, 6: 9. Available from: https://doi.org/10.1200/JGO.19.00227

Ref. 768. Siegel RL, et al. (2022) CA Cancer J Clin, 72: 7. Available from: https://doi.org/10.3322/caac.21708

Ref. 769. Rees CA, et al. (2021) JAMA Pediatr, 175: 1236. Available from: https://doi.org/10.1001/jamapediatrics.2021.3360

Ref. 770. Gallicchio L, et al. (2025) Cancer Causes Control, 36: 587. Available from: https://doi.org/10.1007/s10552-025-01959-8

Ref. 771. Rahimzadeh V, et al. (2022) Pediatr Blood Cancer, 69: e29854. Available from: https://doi.org/10.1002/pbc.29854

Ref. 772. Children’s Brain Tumor Project. Long-Standing Consortium, PBTC, Loses Federal Funding. Accessed: August 31, 2025. Available from: https://www.childrensbraintumorproject.org/2025/08/29/nytimes_pbtc/

Ref. 773. American Journal of Managed Care. Childhood Cancer Awareness Month Spotlights Barriers That Persist in Care. Accessed: September 30, 2025. Available from: https://www.ajmc.com/view/childhood-cancer-awareness-month-spotlights-barriers-that-persist-in-care

Ref. 774. US Food and Drug Administration. Pediatric Oncology Drug Approvals. Accessed: August 31, 2025. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals

Ref. 775. US Food and Drug Administration. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Accessed: August 31, 2025. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications

Ref. 776. National Organization of Rare Diseases. Impact of the Rare Pediatric Disease Priority Review Voucher Program on Drug Development 2012 – 2024. Accessed: August 31, 2025. Available from: https://rarediseases.org/wp-content/uploads/2024/07/NORD-Pediatric-PRV-Report.pdf

Ref. 777. Congress.GOV. H.R.7384 – 118th Congress (2023-2024): Creating Hope Reauthorization Act of 2024. Accessed: Available from: https://www.congress.gov/bill/118th-congress/house-bill/7384

Ref. 778. Friends of Cancer Research. Assessing the Impact of the Research to Accelerate Cures and Equity (RACE) Act. Accessed: August 31, 2025. Available from: https://friendsofcancerresearch.org/blog/assessing-the-impact-of-the-research-to-accelerate-cures-and-equity-race-act/

Ref. 779. Congress.gov. H.R.1231 – 115th Congress (2017-2018): RACE for Children Act. Accessed: August 31, 2025. Available from: https://www.congress.gov/bill/115th-congress/house-bill/1231

Ref. 780. Kids First Data Resource Center. About Kids First Data Resource Center. Accessed: August 31, 2025. Available from: https://kidsfirstdrc.org/about/

Ref. 781. Kids First: A New Vision for Pediatric Research. Accessed: August 31, 2025. Available from: https://kidsfirstdrc.org/kids-first-a-new-vision-for-pediatric-research/

Ref. 782. Alliance for Childhood Cancer. STAR Act : Legislative Activity. Accessed: August 31, 2025. Available from: https://www.allianceforchildhoodcancer.org/legislative-activity/star-act.html

Ref. 783. Sadie Keller Foundation. Looking Back to the Passing of the STAR Act. Accessed: August 31, 2025. Available from: https://sadiekellerfoundation.org/looking-back-to-the-passing-of-the-star-act/

Ref. 784. Centers for Disease Control and Prevention. Tracking Pediatric and Young Adult Cancers. Accessed: August 31, 2025. Available from: https://www.cdc.gov/national-program-cancer-registries/about/pediatric-young-adult-cancer.html

Ref. 785. National Cancer Institute. Childhood Cancer STAR (Survivorship, Treatment, Access, Research) Act (Public Law No: 115-180). Accessed: August 31, 2025. Available from: https://www.cancer.gov/about-nci/legislative/recent-public-laws/star-act

Ref. 786. US Food and Drug Administration. Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee Meeting Announcement – 06/16/2023. Accessed: August 31, 2025. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/june-16-2023-pediatric-oncology-subcommittee-oncologic-drugs-advisory-committee-meeting-announcement

Ref. 787. US Food and Drug Administration. Pediatric Oncology. Accessed: August 31, 2025. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology

Ref. 788. Mittal N, et al. (2022) Scientific Reports, 12: 3875. Available from: https://doi.org/10.1038/s41598-022-07703-5

Ref. 789. Rivers Z, et al. (2023) Clin Ther, 45: 1148. Available from: https://doi.org/10.1016/j.clinthera.2023.08.022

Ref. 790. Lupo PJ, et al. (2020) Cancer Epidemiol Biomarkers Prev, 29: 1081. Available from: https://doi.org/10.1158/1055-9965.Epi-19-0941

Ref. 791. Ohlsen TJD, et al. (2024) Support Care Cancer, 33: 36. Available from: https://doi.org/10.1007/s00520-024-09093-y

Ref. 792. Di Giuseppe G, et al. (2023) Crit Rev Oncol Hematol, 183: 103914. Available from: https://doi.org/10.1016/j.critrevonc.2023.103914

Ref. 793. Congress.gov. S.705 – 119th Congress (2025-2026): Innovation in Pediatric Drugs Act of 2025. Accessed: August 31, 2025. Available from: https://www.congress.gov/bill/119th-congress/senate-bill/705

Ref. 794. Congress.gov. H.R.1262 – 119th Congress (2025-2026): Give Kids a Chance Act of 2025. Accessed: August 31, 2025. Available from: https://www.congress.gov/bill/119th-congress/house-bill/1262/text

Ref. 795. Makurvet FD (2021) Medicine in Drug Discovery, 9: 100075. Available from: https://doi.org/10.1016/j.medidd.2020.100075

Ref. 796. Congress.gov. H.R.3873 – 119th Congress (2025-2026): KO Cancer Act. Accessed: August 31, 2025. Available from: https://www.congress.gov/bill/119th-congress/house-bill/3873

Ref. 797. Congress.gov. H.R.1509 – 119th Congress (2025-2026): Accelerating Kids’ Access to Care Act of 2025. Accessed: August 31, 2025. Available from: https://www.congress.gov/bill/119th-congress/house-bill/1509

Ref. 798. Congress.gov. H.R.1620 – 119th Congress (2025-2026): Finn Sawyer Access to Cancer Testing Act. Accessed: August 31, 2025. Available from: https://www.congress.gov/bill/119th-congress/house-bill/1620

Ref. 799. National Coalition for Cancer Survivorship. Comprehensive Cancer Survivorship Act (CCSA). Accessed: August 31, 2025. Available from: https://canceradvocacy.org/policy/comprehensive-cancer-survivorship-act-ccsa/

Ref. 800. Hunleth J, et al. (2024) EJC Paediatr Oncol, 4. Available from: https://doi.org/10.1016/j.ejcped.2024.100171

Ref. 801. Zettler ME (2022) Expert Rev Anticancer Ther, 22: 317. Available from: https://doi.org/10.1080/14737140.2022.2032664

Ref. 802. Centers for Disease Control and Prevention. United States Cancer Cases and Death Statistics At a Glance. Accessed: August 31, 2025. Available from: https://gis.cdc.gov/Cancer/USCS/#/

Ref. 803. Steliarova-Foucher E, et al. (2017) The Lancet Oncology, 18: 719. Available from: https://doi.org/10.1016/S1470-2045(17)30186-9